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Abstract 
Although it exists mostly as a commensal bacterium colonizing the human nasopharynx, 
particularly in children, the Gram-positive bacterium Streptococcus pneumoniae, is also 
a major human pathogen that can cause a wide range of diseases, which include otitis 
media, sinusitis, pneumonia, and such life-threatening afflictions as bloodstream 
infection and meningitis. 
Created to protect children against pneumococcal disease, the 7-valent pneumococcal 
conjugate vaccine (PCV7) showed high efficacy in preventing disease caused by the 
serotypes included in the vaccine, the so-called vaccine types (VTs). Since colonization 
is an essential first step to develop pneumococcal disease, it is of importance to 
investigate the effect of this vaccine on the degree of colonization, on changes in the 
composition of the nasopharyngeal flora and the virulence potential of the non vaccine 
type (NVT) strains. 
The present thesis is aimed at evaluating the impact of PCV7 on single and multiple 
colonization among Portuguese children by determining the serotypes and clonal types 
of pneumococci replacing the original flora under the influence of the conjugate vaccine. 
The thesis also includes experiments testing the virulence potential of the non vaccine 
serotype strains of pneumococci through the use of animal models. 
First, we conducted a prospective study to evaluate the PCV7 effect on the 
nasopharyngeal colonization, with particular emphasis on drug resistant strains in 
children attending day-care centers in Lisbon, Portugal. Comparison of vaccinated and 
control groups revealed that PCV7 caused replacement of strains expressing vaccine 
serotypes by novel clonal types of pneumococci that produced capsular polysaccharides 
not included in the vaccine. On the other hand, the general rate of carriage of 
pneumococci and the rate of carriage of drug resistant strains has remained unaltered.  
Next, a pilot study was performed to assess the effect of a single dose of the PCV7 
vaccine on the composition of the colonizing flora of individual children. The fact that the 
same children were followed in two sampling periods just one month apart (i.e., before 
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and after vaccination) has allowed assessment of the actual mechanism of the vaccine’s 
effect. In conclusion, in children immunized with a single PCV7 dose a serotype 
replacement phenomenon occurred, both at the population and individual levels. 
Moreover, the PCV7 mode of action relied on the prevention of the de novo acquisition 
of VTs on one hand, and unmasking NVTs on the other. 
In a final study, murine models of colonization and virulence were used to characterize 
the most common penicillin nonsusceptible non vaccine serotypes colonizing the 
nasopharynx of Portuguese children vaccinated with PCV7. Additionally, the role of the 
capsule versus the genetic background in colonization and disease was also 
investigated. In brief, each one of the three major NVTs tested – i.e., strains expressing 
serotypes 6A, 15A, and 19A – were able to colonize and disseminate from the nasal 
epithelium to adjacent tissues, such as the olfactory bulbs, brain, lungs and the middle 
ear mucosa. Each serotype was able to cause lethal lung infection if high bacterial titers 
were reached in the lung. Serotype 19A (ST276) was the only one of the NVTs tested to 
show propensity to cause blood infection. Finally, colonization depended on both the 
capsule and the genetic background, while virulence (i.e. blood infection) was only 
dependent on the capsule.  
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Resumo 
A bactéria Gram-positiva Streptococcus pneumoniae existe normalmente como um 
microrganismo comensal, colonizador da nasofaringe humana, especialmente em 
crianças. Contudo esta bactéria é também um importante agente patogénico humano 
capaz de causar um vasto leque de doenças incluindo otite média, sinusite, pneumonia, 
e ainda patologias que colocam em risco a vida humana como a infecção do sangue e a 
meningite. 
A vacina pneumocócica conjugada 7-valente (PCV7) foi criada para proteger crianças 
contra a doença provocada por S. pneumoniae revelando enorme eficácia na 
prevenção de doença causada pelos serótipos incluídos na vacina, também chamados 
serótipos vacinais. Sendo a colonização um primeiro passo fundamental para o 
desenvolvimento da doença pneumocócica, reveste-se da maior importância a 
investigação do efeito desta vacina no grau de colonização, nas alterações da 
composição da flora da nasofaringe e no potencial de virulência das estirpes não 
vacinais. 
Os objectivos propostos para esta tese levaram à execução de estudos epidemiológicos 
e de experimentação animal. Os estudos epidemiológicos que realizámos permitiram 
avaliar o impacto da vacina PCV7 em colonização simples e múltipla em crianças 
portuguesas identificando os serótipos e os tipos clonais que substituem a flora 
pneumocócica original sob a influência da vacina. Por outro lado, estudou-se o 
potencial de virulência das estirpes pneumocócicas não vacinais seleccionadas pela 
vacina usando modelos animais de colonização e doença. 
Inicialmente realizámos um estudo epidemiológico prospectivo para avaliar o efeito da 
PCV7 na colonização da nasofaringe, com especial incidência nas estirpes resistentes 
a antimicrobianos isoladas de crianças a frequentar infantários na região de Lisboa em 
Portugal. A comparação do grupo vacinado com o grupo controlo mostrou que a PCV7 
causou a substituição dos serótipos vacinais por novos tipos clonais que expressam na 
cápsula polissacáridos (serótipos) não incluídos na vacina. Por outro lado, a taxa de 
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colonização geral por S. pneumoniae e a taxa de colonização por estirpes resistentes a 
antimicrobianos permaneceu inalterada. 
De modo a estudar o efeito de apenas uma dose da vacina PCV7, foi realizado um 
estudo-piloto no qual se estudou além da colonização pneumocócica simples a 
colonização pneumocócica múltipla. O estudo envolveu crianças que foram analisadas 
durante dois períodos de colheita com apenas um mês de intervalo (i.e., antes e depois 
da vacinação), o que permitiu identificar o mecanismo de acção da vacina. Os 
resultados obtidos neste estudo permitiram concluir que em crianças imunizadas com 
apenas uma dose de vacina ocorre um efeito de substituição de serótipos vacinais por 
não vacinais, tanto a nível da população como a nível do indivíduo. Foi possível ainda 
concluir que o mecanismo de acção da PCV7 consiste na prevenção da aquisição de 
novo dos serótipos vacinais por um lado e no “unmasking” de serótipos não vacinais por 
outro. 
No último trabalho apresentado nesta tese foram utilizados modelos murinos de 
colonização e doença. Estes modelos animais serviram para caracterizar os serótipos 
não vacinais e não susceptíveis à penicilina mais comuns, que colonizam a nasofaringe 
de crianças portuguesas vacinadas com a PCV7. O papel da cápsula versus o 
património genético no que diz respeito aos estádios de colonização e doença foi 
também abordado neste estudo. Em resumo, os três serótipos não vacinais mais 
comuns que foram estudados – i.e., estirpes que expressam os serótipos 6A, 15A e 
19A – colonizaram e disseminaram-se em seguida para os tecidos adjacentes à 
nasofaringe, designadamente o bolbo olfactivo, o cérebro, os pulmões e a mucosa do 
ouvido médio. Cada serótipo provocou infecção pulmonar letal quando atingidos títulos 
bacterianos elevados. O serótipo 19A (ST276) foi o único dos serótipos não vacinais 
testado a evidenciar propensão para causar infecção no sangue. Finalmente, 
demonstrou-se que a colonização dependeu da cápsula e do património genético, 
enquanto a virulência (isto é, a infecção do sangue) dependeu apenas da cápsula. 
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Thesis Outline 
The work presented in this Doctoral Thesis describes the evaluation of the impact of the 
7-valent pneumococcal conjugate vaccine (PCV7) on colonization among Portuguese 
children attending day care. This general objective was attained firstly by investigating 
the epidemiology of the pneumococcus, and secondly by assessing the virulence 
potential of non vaccine serotypes selected in vivo by the PCV7 vaccine.  
Chapter I – General introduction. This chapter provides an outline of the Streptococcus 
pneumoniae epidemiology in colonization and disease. The pivotal role of the 
pneumococcal capsule and antibiotic resistance on the development and impact of the 
pneumococcal vaccines is also addressed. Moreover, mouse models are described as 
important and valuable systems to study pneumococcal colonization and pathogenesis. 
Chapter II – Effect of the seven-valent conjugate pneumococcal vaccine on carriage 
and drug resistance of Streptococcus pneumoniae in healthy children attending day-
care centers (DCCs) in Lisbon. This chapter reports, for the first time in Portugal, the 
impact of the PCV7 in colonization and drug resistance among DCC attendees.  
Chapter III – Impact of a single dose of the 7-valent pneumococcal conjugate vaccine 
on colonization. This chapter describes the effect of one PCV7 dose on single and 
multiple carriers, assessing the actual mechanism of the vaccine’s effect.  
Chapter IV – Virulence potential of serotypes selected in vivo by the 7-valent 
pneumococcal conjugate vaccine (PCV7) in Portugal. This chapter presents a study on 
the virulence potential of colonizing non vaccine types selected in vivo by the PCV7 
vaccine using several mouse models.  
Chapter V – Conclusions and perspectives. This chapter combines the major findings of 
this Doctoral thesis, suggesting future follow-ups of these studies. 
Chapters II and III are reproductions of the following publications: 
 xii 
Chapter II – Frazão, N., A. Brito-Avô, C. Simas, J. Saldanha, R. Mato, S. Nunes, N. 
G. Sousa, J. A. Carriço, J. S. Almeida, I. Santos-Sanches, and H. de Lencastre. 
2005. Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug 
resistance of Streptococcus pneumoniae in healthy children attending day-care centers 
in Lisbon. Pediatr Infect Dis J 24:243-52. 
Chapter III – Frazão, N., R. Sá-Leão, and H. de Lencastre. 2010. Impact of a single 
dose of the 7-valent pneumococcal conjugate vaccine on colonization. Vaccine 28:3445-
52. 
 xiii 
List of abbreviations 
A 
AOM – Acute otitis media  
C 
CDC – Centers for Disease Control  
CFU – Colony forming units 
CSF – Cerebrospinal fluid  
D 
DCC – Day-care center 
DR – Drug resistant 
DRPn – Drug resistant Streptococcus pneumoniae 
I 
i.cist. – Intracisternal 
i.n. – Intranasal 
IPD – Invasive pneumococcal disease  
i.p. – Intraperitoneal  
i.t. – Intratracheal 
i.v. – Intravenous  
M 
MIC – Minimum inhibitory concentration 
MLST – Multi-locus sequence typing 
 
 
 xiv 
N 
NCCLS – National Committee for Clinical Laboratory Standards 
NCKP – Northern California Kaiser Permanente 
NP – Nasopharyngeal 
NT – Non typeable  
NVT – Non vaccine type 
P 
PCV7 – 7-valent pneumococcal conjugate vaccine 
PCV13 – 13-valent pneumococcal conjugate vaccine 
PFGE – Pulsed-field gel electrophoresis 
PMEN – Pneumococcal Molecular Epidemiology Network 
Pn – S. pneumoniae 
PNSPn – Penicillin nonsusceptible S. pneumoniae 
PP23 – 23-valent pneumococcal polysaccharide vaccine 
PS – Capsular polysaccharides 
PSPn – Penicillin susceptible S. pneumoniae 
R 
RTI – Respiratory tract infections 
S 
SXT – Trimethoprim-sulfamethoxazole 
V 
VT – Vaccine type 
 xv 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS ................................................................................................V 
ABSTRACT .................................................................................................................VII 
RESUMO ......................................................................................................................IX 
THESIS OUTLINE.........................................................................................................XI 
LIST OF ABBREVIATIONS ........................................................................................XIII 
CHAPTER I .................................................................................................................... 1 
1. General introduction ............................................................................................... 3 
1.1. Streptococcus pneumoniae ................................................................................. 3 
1.2. Historical background .......................................................................................... 4 
1.3. Epidemiology of Streptococcus pneumoniae ....................................................... 5 
1.3.1. Pneumococcal colonization........................................................................... 5 
1.3.2. Pneumococcal disease ................................................................................. 6 
1.3.3. Capsule, antibiotic resistance, and vaccines ................................................. 7 
1.4. Pneumococcal conjugate vaccine...................................................................... 10 
1.4.1. Immunological basis ................................................................................... 10 
1.4.2. Impact on colonization ................................................................................ 11 
1.4.3. Impact on disease....................................................................................... 15 
1.5. Mouse models ................................................................................................... 17 
1.5.1. Mouse model of colonization....................................................................... 18 
1.5.2. Mouse models of pneumococal disease ..................................................... 19 
1.6. Aim of the work.................................................................................................. 25 
1.7. References ........................................................................................................ 27 
CHAPTER II ................................................................................................................. 47 
2. Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug 
resistance of Streptococcus pneumoniae in healthy children attending day-care 
centers in Lisbon. ..................................................................................................... 47 
2.1. Abstract ............................................................................................................. 49 
2.2. Introduction........................................................................................................ 49 
 xvi 
2.3. Materials and Methods ...................................................................................... 51 
2.4. Results .............................................................................................................. 54 
2.5. Discussion ......................................................................................................... 65 
2.6. Acknowledgments.............................................................................................. 67 
2.7. References ........................................................................................................ 69 
CHAPTER III ................................................................................................................ 75 
3. Impact of a single dose of the 7-valent pneumococcal conjugate vaccine on 
colonization .............................................................................................................. 75 
3.1. Abstract ............................................................................................................. 77 
3.2. Introduction........................................................................................................ 77 
3.3. Materials and Methods ...................................................................................... 79 
3.4. Results .............................................................................................................. 82 
3.5. Discussion ......................................................................................................... 91 
3.6. Acknowledgments.............................................................................................. 94 
3.7. References ........................................................................................................ 95 
CHAPTER IV.............................................................................................................. 101 
4. Virulence potential of serotypes selected in vivo by the 7-valent pneumococcal 
conjugate vaccine................................................................................................... 101 
4.1. Abstract ........................................................................................................... 103 
4.2. Introduction...................................................................................................... 103 
4.3. Materials and Methods .................................................................................... 105 
4.4. Results ............................................................................................................ 108 
4.5. Discussion ....................................................................................................... 121 
4.6. Acknowledgments............................................................................................ 124 
4.7. References ...................................................................................................... 125 
CHAPTER V .............................................................................................................. 129 
5. Concluding remarks and future perspectives ...................................................... 131 
5.1. References ...................................................................................................... 137 
 1 
Chapter I 
 
1. General introduction 
 
 2
General introduction 
 3 
1. General introduction 
Streptococcus pneumoniae (the pneumococcus) has been studied for more than a 
century and has so far bypassed all the human initiatives targeted to eliminate this 
apparently unbeatable pathogen. The widespread belief that antimicrobial drugs would 
cure all pneumococcal infections waned the interest in using vaccines to prevent 
infections. Only the emergence of antimicrobial resistant strains led to a recurring 
interest in developing new pneumococcal vaccines that aim to eventually eradicate this 
bacterium. To attain this long-term goal it is essential to be aware of the epidemiological 
dynamics of the pneumococcus. 
Since colonization is the first step to disease development, an in-depth understanding of 
the major pneumococcal serotypes and clones carried in the nasopharyngeal mucosa 
together with data on their virulence potential is critical. Based on this information, it may 
be possible to predict future pneumococcal disease serotypes/genotypes and include 
them in future vaccine formulations. 
1.1. Streptococcus pneumoniae  
Streptococcus pneumoniae, also known as the pneumococcus, is a lancet-shaped 
gram-positive bacterium which can grow in liquid medium as single cells, diplococci or in 
chains. It is a facultative anaerobic microorganism which shows α-hemolysis when 
growing in blood agar plates, solubility when in presence of bile salts, catalase negativity 
and usually susceptibility to optochin. All these characteristics together with common 
positive agglutination with specific antipneumococcal polysaccharide capsule antibodies 
are taken into consideration when classifying a bacterium as belonging to the 
Streptococcus pneumoniae species (Dowson, 2004; Murray, 1999).  
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1.2. Historical background 
In 1875, while searching for a proof of the infectious nature of pneumonia, Edwin Klebs 
was probably the first to recognize S. pneumoniae in pneumonic lung tissue, describing 
the phenomenon as nonmotile, sometimes linked “monads” (White et al., 1938). 
Six years later, in 1881, Louis Pasteur in France and Georg Sternberg in the USA 
reported for the first time the isolation of S. pneumoniae in the laboratory (Pasteur, 
1881; Sternberg, 1881). 
After the discovery of the microorganism, its name changed several times. Pasteur 
called his isolate the “microbe septicémique du saliva” while Sternberg called his 
Micrococcus pasteuri. In 1886, Albert Fraenkel performed the first complete description 
of the microorganism and gave us the familiar name “pneumokokkus”. In the same year 
Anton Weichselbaum suggested the name Diplococcus pneumoniae (White et al., 
1938), which became the official name until 1974 when the organism was reclassified 
Streptococcus pneumoniae according to its characteristic property of growing as chains 
of cocci in liquid media (Bergey, 1974). 
Isolated and characterized more than 120 years ago, S. pneumoniae has been one of 
the most extensively studied microorganisms leading to seminal discoveries in several 
scientific areas, including the putative use of polysaccharide antigens as vaccines 
(Avery et al., 1917), bacterial gene transfer (Griffith, 1928), the isolation and chemical 
characterization of the first polysaccharide antigen (Goebel & Adams, 1943), the 
identification of the “transforming principle” (later named DNA) as the genetic material 
(Avery et al., 1944), the therapeutic efficacy of penicillin (Tillett et al., 1944), the role of 
the bacterial capsule in resistance to phagocytosis (Felton et al., 1955), and the first 
bacterial quorum sensing factor (Tomasz, 1965). 
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1.3. Epidemiology of Streptococcus pneumoniae 
Pasteur and Sternberg, although independently, performed similar experiments when 
they isolated for the first time S. pneumoniae. Both injected human saliva, from 
asymptomatic carriers, into rabbits that died shortly after from blood infection (Pasteur, 
1881; Sternberg, 1881). Altogether, these pioneering experiments showed for the first 
time that S. pneumoniae on one hand can be asymptomatically carried and on the other 
has the potential to cause disease. 
1.3.1. Pneumococcal colonization  
The pneumococcus colonization is described as a commensal relationship with its 
principal host, man (Austrian, 1997). Asymptomatic pneumococcal colonization of the 
human nasopharyngeal mucosa starts immediately after birth (Aniansson et al., 1992) 
and, at any given time, up to 30% of adults and 60% of children are colonized (Austrian, 
1986). The children’s nasopharynx constitutes the major reservoir for the 
pneumococcus, specially day-care center (DCC) attendees where pneumococcal 
colonization rate is particularly high. In Portugal up to 71% of the children up to 6 years 
old attending day-care centers are colonized with pneumococci (Mato et al., 2005).  
Depending on the host’s age and the pneumococcal colonizing strain, the duration of 
carriage ranges between 1 to 17 months (Gray et al., 1980). Pneumococci can present 
two patterns of colonization: i) single colonization, where the host carries only one 
pneumococcal strain or ii) multiple colonization, also called co-colonization, where the 
host carries simultaneously more than one pneumococcal strain, which can differ in 
phenotypic and/or genotypic characteristics (Auranen et al., 2010; Frazão et al., 2010; 
Gray et al., 1980; O'Brien et al., 2007; Sá-Leão et al., 2002). 
Pneumococcal transmission occurs through direct contact with respiratory secretions or 
inhalation of aerosols, from either asymptomatic carriers or from a person with 
pneumococcal disease (Antao & Hausdorff, 2009). Among children, the risk factors 
related to pneumococcal colonization include young age (less than 2 years old), having 
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a sibling and day-care center attendance. Among adults, recurrent contact with children 
and crowdness constitute the major risk factors to be colonized with pneumococci 
(Kristinsson, 1997).  
Pneumococcal colonization is usually studied by performing the characterization of a 
single pneumococcal isolate for each colonized individual. However, studies show that 
individuals can be co-colonized with different pneumococcal strains (Auranen et al., 
2010; Frazão et al., 2010; Gray et al., 1980; O'Brien et al., 2007; Sá-Leão et al., 2002). 
Epidemiological studies based on a single isolate characterization are important and 
valuable tools to detect differences in the pneumococcal dynamics at a population level. 
However, studies where co-colonization is detected are crucial to identify differences at 
the individual level, such as de novo acquisition, clearance and unmasking of 
pneumococcal strains (Dagan et al., 2003; Lipsitch, 1999; Rinta-Kokko et al., 2009).   
1.3.2. Pneumococcal disease 
The pneumococcus is described as being a commensal human pathogen and 
colonization of the nasopharyngeal mucosa is often a transient process (Hill et al., 2008; 
Hogberg et al., 2007), constituting the initial event in the progression to disease 
(Henriques-Normark & Normark, 2010). As a pathogen S. pneumoniae can give rise to a 
wide variety of diseases that can be divided into invasive and non-invasive. In invasive 
pneumococcal disease (e.g. meningitis, bacteremic pneumonia and bloodstream 
infections – bacteremia and septicemia), pneumococcus can be isolated from blood or 
other normally sterile body fluids. In non-invasive pneumococcal disease, also known as 
mucosal infections such as sinusitis, conjunctivitis, non-bacteremic pneumonia and otitis 
media, pneumococcus can be isolated from mucosal excretions only (Bogaert et al., 
2004a; Feldman & Klugman, 1997; Musher, 1992).  
The spectrum of pneumococcal diseases differs in different age groups and different 
populations (Bogaert et al., 2004a; Hausdorff et al., 2005; Musher, 1992; O'Brien & 
Santosham, 2004). Several risk factors for pneumococcal infection, such as viral 
infection, age (less than 5 and over 60 years of age), race, immunodeficiency, chronic 
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underlying illness, socio-economic status, previous antibiotic therapy and day-care 
attendance have been reported (O'Brien & Santosham, 2004). 
Pneumococcus is a leading pathogen, causing infections with high mortality and 
morbidity (Austrian, 1977; Greenwood et al., 2007; Hausdorff et al., 2000a; Hausdorff et 
al., 2000b; Mulholland, 2007; O'Brien & Santosham, 2004; Scott et al., 1996). Up to one 
million children die annually from pneumococcal diseases, and most of them are young 
children in developing countries (O'Brien et al., 2009; WHO, 1999; Williams et al., 2002). 
In industrialized countries invasive pneumococcal infections occur, especially among 
children and elderly people (Eskola et al., 1992; Hausdorff et al., 2005; Sankilampi et al., 
1997; Scott et al., 1996).  
1.3.3. Capsule, antibiotic resistance, and vaccines  
In the overwhelming majority of pneumococcal isolates the outside surface of the 
bacterium is covered by a polysaccharide capsule, which plays a major role in 
colonization and disease and constitutes the main virulence factor of S. pneumoniae. 
The chemical nature of the capsule and the amount of capsule produced are major 
factors inhibiting complement activity, neutrophil phagocytosis, and bacterial killing by 
neutrophil extracellular traps (Hyams et al., ; Kim & Weiser, 1998; Kim et al., 1999; 
Macleod & Krauss, 1950; Magee & Yother, 2001; Nelson et al., 2007; Paton et al., 1993; 
Quin et al., 2007). The capsule also plays a major role in bacterial interactions with the 
epithelium in colonization (Bootsma et al., 2007; Macleod & Krauss, 1950; Magee & 
Yother, 2001; Nelson et al., 2007; Quin et al., 2007; Wartha et al., 2007).  
The pneumococcal capsules are very diverse in chemical structure and a nomenclature 
system was created based on the antigenic differences of the capsular polysaccharides 
(PS) grouping the capsules into more than 90 serotypes (Austrian, 1981; Henrichsen, 
1999; Sorensen, 1995). In recent years additional new serotypes 6C, 6D and 11E were 
discovered, suggesting that the diversity of pneumococcal capsules is even greater than 
was previously recognized (Calix & Nahm, 2010; Henrichsen, 1995; Jin et al., 2009; 
Oftadeh et al., 2010; Park et al., 2007b).  
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Shortly after the pneumococcal capsule was identified as a major immunogen in the 
1930’s, vaccine development focused on purified PS culminating with the 
commercialization of two hexavalent polysaccharide vaccines in 1946 in the United 
States (Felton, 1938; Francis & Tillett, 1930). Concomitantly, sulfonamides and penicillin 
had become readily available and new antimicrobial drugs were on the way. The 
discovery of antimicrobials paved the way for better health for millions around the world. 
Before penicillin became a viable medical treatment in the early 1940's, no true cure for 
gonorrhea, strep throat, or pneumonia existed. Patients with infected wounds often had 
to have a wounded limb removed, or face death from infection. The dawn of 
antimicrobial drugs enabled all these fierce medical conditions to be cured with a short 
course of antimicrobial treatment. Thus, the vaccines were forgotten and were 
withdrawn from the market in 1954 for lack of demand (Fedson et al., 1994). However, it 
did not take long before it became clear that antimicrobials had not eliminated 
pneumococcal disease. 
Resistance to antimicrobials is closely linked to the fact that S. pneumoniae is a 
naturally transformable bacterium. Pneumococci, when in a competent state, have the 
capacity of taking up DNA and incorporate it into their genome (Claverys & Havarstein, 
2007). Whenever the DNA incorporated into the genome has resistance genes the 
pneumococci become resistant to drugs. 
In 1964, a study by Austrian and Gold reported that nearly one in four patients admitted 
with pneumococcal bacteremia died even with antimicrobial drug treatment (Austrian & 
Gold, 1964). In 1967, the first intermediately penicillin resistant pneumococcal isolate 
was reported in Australia (Hansman & Bullen, 1967). In the following years penicillin 
remained the drug of choice to treat pneumococcal infections as resistance to other 
drugs such as tetracyclines, chloramphenicol, macrolides, and trimethoprim-
sulfamethoxazole (SXT) had emerged (Klugman, 1990). In 1978, the first pneumococcal 
strains resistant to all the above mentioned antimicrobial classes, as well as fully 
resistant to penicillin, were isolated (Jacobs et al., 1978). It was the beginning of the 
pneumococcal multidrug resistance (resistance to three or more classes of drugs) era. 
During the 1980’s, multidrug resistant strains were found in Spain and spread globally 
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(Klugman, 1990). In the 1990s, multidrug resistance continued to increase such that in 
the United States in 2000 nearly half of all invasive pneumococcal disease (IPD) was 
caused by pneumococcal isolates resistant to penicillin and/or macrolides (Whitney et 
al., 2000).  
The widespread belief that antimicrobials alone would “solve” all pneumococcal 
infections was definitely put aside as soon as pneumococcal drug resistance became a 
reality causing treatment failures (Kaplan & Mason, 2002). Consequently, a renewed 
interest in the prevention through vaccination was regained and led to clinical trials of a 
PS vaccine. In 1977 the Merck’s 14-valent pneumococcal polysaccharide vaccine 
(Pneumovax) was licensed in the United States. Similar 14-valent vaccines were later 
produced by Lederle (Pnu-Immune) and by Pasteur Mérieux. The 14 PS types included 
in these vaccines (1, 2, 3, 4, 6A, 7F, 8, 9N, 12F, 14, 18C, 19F, 23F, and 25F) were 
selected based on epidemiological information from the United States, parts of Europe, 
and South Africa, being the most common serotypes causing pneumococcal disease 
(Robbins et al., 1983). In 1983 the 14-valent vaccine was expanded to include 23 PS 
types, and is currently the only approved formulation available for adults in the United 
States (Fedson & Musher, 2004; Siber, 1994). 
The main disadvantage of the 23-valent vaccine is the fact that it is not effective in 
children less than two years old, who are at highest risk of life-threatening 
pneumococcal infection and acute otitis media (CDC, 2000; Makela & Butler, 2008). To 
overcome this major weakness the concept of pneumococcal conjugate vaccine was 
developed. The novelty of these conjugate vaccines is the fact that PS types instead of 
being “presented” alone to the child’s immune system are attached to an immunogenic 
carrier protein that allows a highly efficient antibody production and induces 
immunological memory. 
The 7-valent pneumococcal conjugate vaccine (PCV7) was the first conjugate vaccine to 
be licensed. It began to be marketed in 2000 and includes the seven most common 
serotypes isolated from the blood or cerebrospinal fluid (CSF) of children under 6 years 
old (i.e., 4, 9V, 6B, 14, 18C, 19F and 23F) in the United States (CDC, 2000). In Portugal 
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PCV7 was introduced in June 2001 and, despite widespread vaccination, it is still not 
part of the national vaccination plan. 
Very recently, higher valency pneumococcal conjugate vaccines were licensed such as 
PCV10 (10-valent pneumococcal conjugate vaccine), which includes the PCV7 
serotypes plus serotypes 1, 5, and 7F. PCV13 (13-valent pneumococcal conjugate 
vaccine) was the last to be licensed and includes PCV10 serotypes plus serotypes 3, 
6A, and 19A. 
1.4. Pneumococcal conjugate vaccine 
The pneumococcal conjugate vaccine was a big step forward to win the apparently 
never-ending war against the S. pneumoniae pathogen, especially in children under two 
years of age who are at higher risk of contracting pneumococcal infections. This age 
group is not immunologically responsive to the 23-valent pneumococcal polysaccharide 
vaccine, but is protected by a pneumococcal conjugate vaccine.  
1.4.1. Immunological basis  
The primary pneumococcal antigens eliciting a host immune response are the 
pneumococcal capsular polysaccharides, which induce a T-cell independent immune 
response that is virtually absent in children until around two years of age. Conversely, 
when capsular polysaccharides are covalently coupled to immunogenic proteins such as 
the mutant diphtheria toxin CRM197 used in PCV7, a T-cell dependent response is 
elicited. This type of immunological response is already present in children aged up to 
two years, thus rendering conjugate vaccines a good immunogen for this age group. 
Another major characteristic of T-cell dependent responses is the induction of 
immunological memory characterized by affinity maturation and a booster response on 
subsequent exposure to the bacterial antigen. In summary, a conjugate vaccine induces 
T-cell dependent immunity in young children, which leads to effective antibody 
production and immunologic memory. 
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The pneumococcal conjugate vaccine can confer both systemic and mucosal immunity 
(Korkeila et al., 2000; Nieminen et al., 1999; Nurkka et al., 2001a). The immunological 
protection is mediated through the production of specific antibodies. Mucosal immunity 
is mainly mediated through the production of serotype-specific immunoglobulin A (IgA) 
antibodies, which are locally produced at the nasopharyngeal mucosa (Choo et al., 
2000; Korkeila et al., 2000; Nurkka et al., 2001a). Serotype-specific immunoglobulin G 
(IgG) antibodies are mainly found in serum, conferring systemic immunity. However, 
they can also be detected in the nasopharyngeal mucosa, although more rarely than IgA 
(Choo et al., 2000; Kauppi et al., 1995; Korkeila et al., 2000; Nurkka et al., 2001a; 
Nurkka et al., 2001b). It is believed that circulating IgG antibodies can passively cross 
the nasal mucous membrane and help prevent pneumococcal colonization, though 
mucosal IgG production has been suggested to happen as well  (Berneman et al., 1998; 
Ogra, 2000). 
1.4.2. Impact on colonization  
The impact of the 7-valent pneumococcal conjugate vaccine on colonization can have 
both a direct effect — protecting those successfully immunized from carriage — and an 
indirect effect — providing protection against carriage among unimmunized individuals 
by reducing transmission of the organism within the community.  
The vaccination schedule varies between countries, but all the primary PCV7 
immunization series include two or three vaccine doses between 6 weeks and 6 months 
of age. A booster dose in the second year of life is the recommended practice in 
economically developed countries, but is not included in the schedules of developing 
countries due to the high price of the vaccine (ACIP, 2000). Studies of the effect in 
colonization of fewer than the recommended doses are scarce. A mathematical model of 
vaccination suggested that a single dose given between 5 and 7 months of age could 
prevent up to one-third of invasive pneumococcal disease (Barzilay et al., 2006). 
Bearing in mind that disease is preceded by colonization, studying the impact of less 
than the recommended vaccine doses in colonization may play a major role for the 
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development of less expensive vaccine schedules that eventually may foster the 
introduction of pneumococcal vaccines in developing countries.  
The major conclusion concerning the direct effect of the conjugate vaccines is that in 
vaccinated individuals there is a reduction in the prevalence of nasopharyngeal 
colonization by the serotypes included in the pneumococcal conjugate vaccines. This 
general effect has been shown in children after a primary PCV immunization series 
(Dagan et al., 1997; Mbelle et al., 1999; O'Brien et al., 2007), or after a boosting dose of 
either the 23-valent polysaccharide or conjugate vaccines (Dagan et al., 1997; Dagan et 
al., 2000; Kilpi et al., 2001; Obaro et al., 1996). 
In the specific case of children attending DCCs, where colonization rates are normally 
very high (Dagan et al., 1996a; Dagan et al., 2002; Dagan et al., 2005; Frazão et al., 
2005), the pneumococcal conjugate vaccine also showed efficacy in reducing the 
colonization by vaccine serotype strains. The same effect of reducing vaccine type 
colonization was also reported when immunization was carried out with fewer than the 
recommended conjugate vaccine doses (Frazão et al., 2010; Jones et al., 2005; van 
Gils et al., 2009) 
The above mentioned effect has been reported for all serotypes in the pneumococcal 
conjugate vaccine formulation. However, in some studies, the effect on serotype 19F is 
reported as being the lowest (Dagan et al., 2002; Dagan et al., 2005; Huang et al., 2005; 
Millar et al., 2006; Veenhoven et al., 2003). Concerning the vaccine related serotypes, 
the ones belonging to the same serogroups, 6A prevalence decreases in vaccinated 
individuals whereas 19A and 23A prevalence increases (Huang et al., 2005; Millar et al., 
2006; Sá-Leão et al., 2009; Veenhoven et al., 2003). Regarding the non vaccine 
serotypes, there is an increase in vaccinated children when compared to non vaccinated 
children (Dagan et al., 1996a; Dagan et al., 1997; Dagan, 2002; Frazão et al., 2005; 
Frazão et al., 2010; Sá-Leão et al., 2009). The immune response to the pneumococcal 
conjugate vaccines confers direct protection against the vaccine types (VTs) in the 
nasopharynx. The ecological mechanism(s) by which the pneumococcal conjugate 
vaccines act directly against the vaccine types is not addressed in the majority of the 
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studies. However, there are strong indications that the primary mechanism of the 
vaccines’ effect is the prevention of the de novo acquisition of VTs, rather than 
clearance, and additionally the reduction of the density of colonization by the vaccine 
serotypes (Dagan et al., 2005; Frazão et al., 2010; O'Brien et al., 2007). 
The reduction in the VT pneumococcal carriage due to the PCV thus opens a biological 
niche that is filled by non vaccine type (NVT) strains leading to a phenomenon which 
has been termed as serotype replacement colonization. The colonization of the 
nasopharynx with serotypes not included in the vaccine (NVTs) can happen through i) 
capsular serotype switching, such that previous vaccine type clones exhibit now NVT 
capsules, ii) the expansion and propagation of existing NVT clones in the community, 
and iii) the introduction of new NVT clones into the community.  
Worth to be investigated should be the “unmasking” phenomenon in which a minority 
clone/serotype is masked by a dominant clone/serotype in hosts that carry more than 
one type of pneumococci at the same time. This can only be addressed if multiple 
colonization (co-colonization) studies are undertaken. These studies may clarify whether 
the new NVT clones/serotypes are in fact new or simply types already present but 
masked and unidentified by approaches where only a single pneumococcal isolate per 
sample was recovered.  
As a rule of thumb, the final result of the direct impact of the pneumococcal conjugate 
vaccines in colonization is that serotype replacement carriage occurs, meaning that 
vaccine types are substituted by non vaccine serotypes. This massive direct effect of 
PCV in pneumococcal colonization among vaccinated children results in a low or 
inhibited transmission of vaccine types within households, day-care attendees, and 
communities as a whole, leading also to serotype replacement of vaccine by non 
vaccine types just as is known to happen in vaccinated children. This effect of PCV on 
unimmunized individuals is termed the indirect or herd immunity effect, which was 
shown in numerous studies. Indeed, immunization of children with a pneumococcal 
conjugate vaccine was shown to decrease vaccine serotype colonization in children too 
young to be immunized (under 2 months) and older children and adults who are not 
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eligible for vaccination, pointing at the same time to an increased prevalence of non 
vaccine serotypes colonizing the nasopharynx of unvaccinated individuals (Givon-Lavi et 
al., 2003; Hammitt et al., 2006; Hennessy et al., 2005; Moore et al., 2004; O'Brien et al., 
2007).  
The effect of the pneumococcal conjugate vaccine on antibiotic resistance is explained 
by the fact that the global pandemic of pneumococcal resistance was dominated by a 
relatively small number of resistant and multidrug resistant clones that express mainly 
five (6B, 9V, 14, 19F, and 23F) of the seven serotypes included in the PCV7 vaccine 
(Dagan & Klugman, 2008; Kyaw et al., 2006; McGee et al., 2001). Since both the direct 
and indirect effects of the pneumococcal conjugate vaccine on colonization lead to the 
decrease of the VTs, which are strongly associated with resistance, particularly high-
level penicillin resistance and multidrug resistance, one can expect that vaccination with 
a pneumococcal vaccine will reduce the prevalence of antibiotic resistant S. 
pneumoniae strains. In fact, studies in Israel, where multi-valent pneumococcal 
conjugate vaccines were used to immunize children, reported a reduction in the drug 
resistant pneumococcal strains colonizing the nasopharynx (Dagan et al., 1996a; Dagan 
et al., 1997; Dagan et al., 2000; Dagan et al., 2003; Mbelle et al., 1999). Nevertheless, 
in some locations the increasing prevalence of NVTs, also drug resistant, as a result of 
the serotype replacement phenomenon led to a compensatory effect that allows the 
maintenance of pneumococcal drug resistance in the populations. In Portugal, after 
vaccination with the PCV7 the carriage rate of drug resistant pneumococcal strains 
exhibiting vaccine capsular types decreased, but was compensated by a gradual 
increase in the prevalence of drug resistant NVTs, nonsusceptible to penicillin (6A, 6C, 
10A, 15A, 15B/C, 19A, 24F and 33F) (Frazão et al., 2005; Sá-Leão et al., 2009). In the 
United States, a similar trend was found (Huang et al., 2005). In PCV7 vaccinated 
children, parallel to the decrease of drug resistant VTs, a substantial increase in NVTs 
was seen, namely in the most commonly carried penicillin nonsusceptible serotypes: 6A, 
19A, 23A and serogroups 15 and 29 (Huang et al., 2005). 
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Moore and co-workers also found the same serotype dynamics in vaccinated children 
where the carriage of penicillin nonsusceptible strains was maintained after vaccination 
with PCV7 (Moore et al., 2004). 
Possible explanations for the rise of drug resistant strains after vaccination with a 
pneumococcal conjugate vaccine include the de novo acquisition of resistance, serotype 
switching, the introduction of new clones, and the expansion of existing clones. In 
Portugal the increase of drug resistance among the non vaccine type population (6A, 
10A, 15A, 15B/C, 19A, 23A, and 33F) seems to be due to the de novo acquisition of 
resistance (a rare phenomenon only observed for serotype 10A) and, most frequently, 
the introduction of new clones and the expansion of existing ones (Frazão et al., 2007). 
Hanage and co-workers, observed a similar scenario where resistance increased mainly 
through the expansion of pre-existent clones of non vaccine serotypes, particularly 15A, 
19A, and 35B (Hanage et al., 2007). 
1.4.3. Impact on disease 
The direct effect of the 7-valent pneumococcal conjugate vaccines translates into a 
sharp decline of invasive disease among immunized children caused by S. pneumoniae 
serotypes included in its formulation (Aguiar et al., 2008; Aguiar et al., 2010; Bettinger et 
al., 2010; Black et al., 2004; Dagan et al., 2001; Hennessy et al., 2005; Hsu et al., 2005; 
Kellner et al., 2005; Munoz-Almagro et al., 2008; Pilishvili et al., 2010).  
Concerning the efficacy of PCV7, data from the Northern California Kaiser Permanent 
health system (NCKP), which conducted the first clinical trial to evaluate PCV7, 
demonstrated an efficacy of 97% against invasive pneumococcal disease (IPD)  caused 
by the vaccine serotypes (Black et al., 2000). After the PCV7 licensure in 2000 in the 
United States, a population-based study from the Active Bacterial Core Surveillance of 
the Centers for Disease Control (CDC) and Prevention reported a large IPD reduction 
from 24.3 cases in 1998-1999 to 17.3 per 100000 in 2001. The main decline was 
observed in children younger than two years old showing a 78% decrease in the rate of 
IPD caused by the vaccine serotypes (Whitney et al., 2003). 
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Regarding the pneumococcal non-invasive mucosal disease, the impact of the 
pneumococcal conjugate vaccine was confirmed although considered moderate. The 
estimated efficacy of PCV7 in preventing first episodes of radiographic pneumonia was 
30% (Hansen et al., 2006). Additionally, studies based on data from the NCKP showed 
a 7% efficacy in preventing episodes of otitis media, a disease with high burden and 
associated related costs. The same was found in the FinOM trial (Black et al., 2000; 
Eskola et al., 2001; Kilpi et al., 2001).  
Just like in the colonization phenomenon, in disease too, the pneumococcal conjugate 
vaccine was also accompanied by an indirect effect. The rationale for this relies on the 
fact that by immunizing a subset of a population (children) one can reduce significantly 
the circulation of vaccine types, reducing carriage and even more the disease caused by 
these serotypes, among the non-vaccinated individuals. Evidence for this indirect or 
herd immunity effect, described early after PCV7 licensure, highlights an important 
component of the public health profit of pneumococcal conjugate vaccine use. A report 
from the NCKP study indicated that the reduction in disease was greater than the 
percentage of children vaccinated (Black et al., 2001). A similar pattern was observed in 
the CDC data where the rate of vaccine type disease among children less than 5 years 
old dropped 94%, even though only 68% of children had been vaccinated (CDC, 2005). 
Reported decrease of IPD caused by vaccine types among children too young to be 
immunized (under 2 months) and older children and adults who are not eligible for 
vaccination further confirm the herd immunity effect of the pneumococcal conjugate 
vaccine (Black et al., 2004; Poehling et al., 2006; Whitney et al., 2003). 
The overall reduction of the disease-causing vaccine serotypes in settings where 
pneumococcal conjugate vaccines were administered raised an expectancy of 
decreasing the overall pneumococcal drug resistance. This expectation is based on the 
fact that five of the serotypes included in the conjugate vaccine (6B, 9V, 14, 19F, and 
23F) were responsible for the prevalence of drug resistance among pneumococci. 
Indeed, several studies reported large decreases in disease episodes caused by drug 
resistant pneumococci (Hennessy et al., 2005; Kaplan et al., 2004; Klugman et al., 2003; 
Kyaw et al., 2006). However, at the same time that the decline in disease in general, 
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and that caused by drug resistant pneumococci in particular, were observed, an 
increase in disease caused by non vaccine types, namely resistant to drugs, was 
reported (Byington et al., 2005; Eskola et al., 2001; Hicks et al., 2007; Porat et al., 
2004). The substitution of vaccine by non vaccine serotypes in disease due to the 
selective pressure exerted by the conjugate vaccine is called replacement disease. 
Early studies of the impact of vaccination found that, among children, increases in the 
rate of disease due to non vaccine serotypes were either small in magnitude or limited to 
a single geographic location (Byington et al., 2005; Flannery et al., 2004; Kaplan et al., 
2004). It was hoped that IPD caused by non vaccine types such as 6A, and 19A could 
be prevented through cross protection with serotypes 6B and 19F included in the PCV7. 
Although this reduction has been reported for serotype 6A (Millar et al., 2006; Whitney et 
al., 2003), an increase rather than a decrease in serotype 19A IPD has been observed 
(Beall et al., 2006; Hennessy et al., 2005; Pai et al., 2005). More recent data showed 
larger increases in the incidence of serotype 19A and serogroup 15 strains among 
children and of multiple non vaccine serotypes among adults, specially with HIV/AIDS, 
where the infection with S. pneumoniae occurs up to 100 times more frequently than 
among the general population (Aguiar et al., 2010; Dworkin et al., 2001; Flannery et al., 
2006; Hicks et al., 2007; Munoz-Almagro et al., 2008; Nuorti et al., 2000; Pai et al., 
2005). 
In just a few years after the licensing of the PCV7 vaccine, serotype 19A has become 
the predominant cause of invasive disease in children and, not less importantly as it can 
lead to medical treatment  failures, increasingly drug resistant (Aguiar et al., 2010; Hicks 
et al., 2007; Munoz-Almagro et al., 2008; Pai et al., 2005). 
1.5. Mouse models  
Experimental animal models have been used extensively to understand vital processes 
of the pneumococcal colonization and disease (Chiavolini et al., 2008; Malley & Weiser, 
2008). Mouse models have been playing a vital role concerning much of what has been 
learned on these topics, serving as surrogates for the same phenomena in humans.  
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1.5.1. Mouse model of colonization  
The pneumococcal colonization is a crucial step for invasive disease development, 
rendering the in vivo study of this phenomenon fundamental to complement 
epidemiological and in vitro studies. 
The mouse model is the most widely used for studying pneumococcal colonization, for a 
number of reasons: i) mice are colonized by pneumococci of multiple serotypes, ii) there 
is availability of reagents and diversity of mice strains (such as CD1, C57BL/6, BALB/c, 
and CBA/n), iii) the intranasal inoculation of anesthetized mice with selected strains can 
subsequently lead to disease, in a way that mimics natural pneumococcal infections in 
humans (Balachandran et al., 2002; Takashima et al., 1997; Wu et al., 1997), and iv) the 
persistence of colonization in mice was shown to last several weeks, which again may 
be viewed as representative of what may happen in humans (Gray et al., 1980; Hogberg 
et al., 2007; McCool & Weiser, 2004). Moreover, the characterization of experimental 
nasal colonization in humans provided a basis for assessing the applicability of the 
mouse models of colonization. An example of this is the fact that the same isolate used 
in human studies was found to colonize mice in association with a similar inoculum 
dose, duration, and immune response (McCool & Weiser, 2004).  
Several variations of the model have been used, but in the majority of cases, a 10-µl 
bacterial inoculum is intranasally dropped atraumatically into the nares of the mice. After 
inoculation the presence and density of pneumococcal colonization can be investigated 
over the subsequent days, generally by obtaining nasopharyngeal washes from recently 
euthanized animals (Wu et al., 1997).  
Several limitations have been attributed to the mouse model, such as the fact that 
different laboratories have used different mouse strains, which can vary in susceptibility 
to colonization and may prevent reproducibility of results. More specifically, much of the 
research work has been carried out using mainly the D39 isolate (Iannelli et al., 1999), 
which is useful for studying invasive disease but colonizes mice relatively inefficiently 
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when compared to other pneumococcal isolates (Lipsitch et al., 2007; van Ginkel et al., 
2003; Wu et al., 1997). 
Mouse models have provided important information on the pneumococcal commensal 
state, colonization. For example, using a mouse model it was shown that a minimum 
amount of capsular polysaccharide is needed for efficient colonization, and that 
unencapsulated mutants remain capable of colonizing but at a lower density and 
duration when compared with the capsulated parental strains (Magee & Yother, 2001; 
Nelson et al., 2007). Regarding prevention strategies to avoid colonization by using 
protein vaccines, it was shown in a mouse model that the choline-binding protein A 
(CbpA), also named PspC or SpsA, is crucial for pneumococcal colonization and that 
another choline-binding surface protein, PspA, can elicit a mucosal immune response 
that may confer protection against colonization (Balachandran et al., 2002; Rosenow et 
al., 1997). 
Also the ease of use of genetically modified mice allows the characterization of host 
factors essential in colonization. Studies which examined the time course of colonization 
using genetically modified mice showed that pneumococcal clearance in the 
nasopharynx is dependent on members of a family of Toll-like receptors, which 
recognize pathogen associated patterns and lead to efficient clearance of colonization 
(van Rossum et al., 2005). In recent years, McCool and Weiser showed, using a mouse 
model of colonization, that pneumococcal colonization occurs in an antibody-
independent manner (McCool & Weiser, 2004).   
1.5.2. Mouse models of pneumococal disease  
Pneumococcal disease can range from mild to life-threatening infections. Similarly to 
what happens with colonization, the most commonly used animal model for 
pneumococcal disease is the mouse.  
A multiplicity of mouse strains that includes inbred mice, BALB/c, C57BL/6, DBA, and 
CBA and outbred mice, MF1, CD1, Swiss-Wbster and NMRI is used to study the widely 
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diverse scenarios of pneumococcal disease, such as pneumonia, septicemia, 
meningitis, and otitis media (Briles et al., 1981; Canvin et al., 1995; Iizawa et al., 1996; 
Melhus & Ryan, 2003; Shapiro et al., 2000; Wang et al., 2001; Zwijnenburg et al., 2001). 
The mouse outbred strains have become increasingly popular because they maintain 
the maximum heterozygosity, which leads to a phenotypic diversity resembling that of 
humans. This feature is important as it mimics the natural variation in response to 
infection in humans. Moreover, the lower cost of these outbred mice strains makes them 
attractive alternatives to inbred strains. 
1.5.2.1. Pneumonia model  
Mouse models of pneumococcal pneumonia allow the analysis of various parameters 
such as survival after challenge, bacterial presence in lungs and blood, inflammation 
levels, and histology of lung tissue. Additionally, quantification of antibody titers and 
antimicrobials performed in vaccine and drug pharmacokinetic studies, respectively, are 
also feasible. Two main routes of infection are currently used to induce pneumonia: the 
intratracheal (i.t.) and the intranasal (i.n.) route. 
The i.t. model is a complex and invasive technique, but has the advantage of allowing 
the delivery of the entire bacterial inoculum into the lower respiratory tract directly 
causing pneumonia (Rubins et al., 1996). Briefly, the bacterial suspension is injected 
trough the mouse oropharynx or through the mouse exposed or cannulated trachea into 
the lungs (Azoulay-Dupuis et al., 1991; Iwasaki et al., 1999; Tasaka et al., 2002).  
The i.t. model is still used in studies of drug efficacy, host response to infection, and the 
role of pneumococcal virulence factors in the disease process (Abgueguen et al., 2007; 
Mohler et al., 2003; Rubins et al., 1996). 
The i.n. model is a simple and non-invasive technique which includes both the standard 
aspiration method (Canvin et al., 1995) and the aerosol nebulizer system (Nuermberger 
et al., 2005). The model of i.n. aspiration to cause pneumonia is the most commonly 
used because it is fast and easy to perform and, most importantly, mimics the natural 
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route of infection in humans. Briefly, a volume of bacterial inoculum higher than 10 µL is 
intranasally dropped atraumatically into the nares of anesthetized mice. The model of 
i.n. aerosol system requires an exposure chamber equipped with a nebulizer. This 
aerosol technique less closely resembles the development of pneumococcal pneumonia 
in humans, where the disease generally follows aspiration of bacteria from the upper 
respiratory tract. 
Studies on the host immune response to lung infection, the role of virulence 
determinants, mice susceptibility and resistance to disease, the efficacy of antibiotics 
and anti-inflamatory drugs and even studies on protection from i.n. challenge after 
immunization with vaccine candidates have been carried out using the pneumonia 
mouse model (Alexander et al., 1994; Bergeron et al., 1998; Blue et al., 2003; Coil et al., 
1978; Gingles et al., 2001; Wang et al., 2000; Wang et al., 2005).  
1.5.2.2. Septicemia model  
The mouse is the most common experimental animal used to study septicemia induced 
by S. pneumoniae. The occurrence of pneumococcal septicemia in mice is assessed 
mostly by determining the presence of bacteria in the blood and by observing post-
challenge survival. Pneumococcal septicemia is induced in the mouse either by injecting 
bacteria directly into the bloodstream (i.v.) or by injection into the peritoneal cavity (i.p.). 
In brief, the i.v. model consists of an injection of the bacterial suspension into the mouse 
tail vein. Due to the reduced size of the mouse vein, an infrared lamp is used to allow 
vasodilatation and facilitate the procedure. The i.p. route of infection is one of the 
earliest techniques used to induce septicemia and consists of an injection of the 
bacterial suspension into the peritoneal cavity, which leads to posterior infection of the 
blood. The i.v. model of infection is a more direct system than the i.p. model. However, 
the former can be time-consuming and difficult to perform comparing to the i.p. route, 
which is technically easier but presents disadvantages including the risk of tissue 
damage or pain to the animal (Briles et al., 1992; Iannelli et al., 2004).  
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Studies that aimed to investigate the role of virulence factors during septicemia, the 
efficacy of potential vaccines and of novel antimicrobials, as well as blood clearance 
mechanisms have been performed using the septicemia mouse model (Benton et al., 
1995; Briles et al., 1981; Briles et al., 1992; Brown et al., 2001; Cao et al., 2007; Casal 
et al., 2002; Iannelli et al., 2004; Loeffler et al., 2003; Ogunniyi et al., 2007; Swiatlo et 
al., 2003). 
1.5.2.3. Meningitis model  
Only recently has the mouse become an experimental system for studying meningitis 
induced by S. pneumoniae.  
There are two main types of procedures to induce pneumococcal meningitis in mice – a 
direct infection by intracerebral or the intracisternal (i.cist.) route and infection via the 
blood route (i.p. or i.n.). A third route was recently described by van Ginkel and co-
workers, in which pneumococci colonize the nasopharynx and enter the central nervous 
system along the olfactory nerves without causing blood infection. The latter contradicts 
the assumption that pneumococci induce meningitis only by invasion via the blood (van 
Ginkel et al., 2003). 
The direct infection of the central nervous system mimics the contiguous spread of 
pneumococci infecting the sinuses or middle ear or the direct infection due to trauma. It 
is an experimental system that allows the study of host-pneumococci interactions once 
the disease is established, but does not allow the study of the previous steps that occur 
from colonization to disease (Koedel et al., 2002). Conversely, meningitis induced via 
i.n. or i.p. routes allows the analysis of pathogenesis according to what is believed to be 
the natural route of infection. However, a major disadvantage is the fact that using this 
technique ~50% of the mice die due to septicemia even before developing meningitis 
(Tsao et al., 2002; Zwijnenburg et al., 2001).  
The characterization of meningitis in the mouse model has been carried out by 
assessing different parameters, including mice survival, clinical scores, bacterial 
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presence in the brain and cerebrospinal fluid, histological analysis, and determination of 
leukocyte and cytokine levels (Gerber et al., 2001; Grandgirard et al., 2007; Koedel et 
al., 2001; Marra & Brigham, 2001; Tan et al., 1995). 
Studies on the efficacy of antimicrobials against meningitis, host and pneumococcal 
virulence factors involved in meningitis pathogenesis, and the assessment of 
postinfectious sequelae have been performed using the meningitis mouse model 
(Bottcher et al., 2003; Echchannaoui et al., 2002; Iizawa et al., 1998; Kostyukova et al., 
1995; Nau et al., 1999; Shapiro et al., 2000; Wellmer et al., 2000). 
1.5.2.4. Otitis media model  
The interest in using the mouse as a model for otitis media has been growing in recent 
years as mice present advantages when compared to other animal systems, including 
lower price and a better characterization regarding immunological and genetic 
information. Drawbacks of using the mouse as an otitis media model include its small 
size together with the reduced accessibility of the middle ear for inoculation and 
sampling purposes.  
In the mouse model of otitis media two different routes are used: direct injection 
(intratympanic or intrabullar) into the middle ear, and the i.n. route that mimics the 
natural mode of middle ear infection. Briefly, in the direct injection there is a direct 
application of the inoculum into the middle ear cavity either through the tympanic 
membrane or by exposing the bulla and injecting the bacterial suspension through the 
bony wall using a thin needle (Ryan et al., 2006; Sabirov & Metzger, 2006). In the i.n. 
route, an intranasal inoculation is performed to establish colonization of the 
nasopharynx, which is followed by invasion of the middle ear cavity by the pneumococci 
in about 50% of the cases (Ryan et al., 2006; Sabirov & Metzger, 2008). 
Recently, in 2009, a very elegant model was proposed by Stol and co-workers, in which 
anesthetized mice receive 10 µL of the pneumococcal suspension in a similar way as in 
the colonization model. By using a pressure cabin, a 40 kPa pressure increase is 
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applied to translocate pneumococci from the nasopharyngeal cavity into both mouse 
middle ears (Stol et al., 2009) 
Studies on potential vaccines and new therapies, pneumococcal virulence factors, 
inflammation, and histology have been carried out using the otitis media mouse model 
(MacArthur et al., 2006; McCoy et al., 2005; McCullers et al., 2007; Melhus & Ryan, 
2003; Sabirov & Metzger, 2006; Sabirov & Metzger, 2008; Stol et al., 2009). 
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1.6. Aim of the work 
S. pneumoniae is a colonizer of the nasopharyngeal mucosa in young children. 
Pneumococcal disease takes place after colonization and can range from mild to fatal 
infections. PCV7 was the first pneumococcal conjugate vaccine created to overcome the 
lack of efficacy of the 23-valent polysacharide vaccine in young children. The aim of this 
thesis was two-fold: i) to evaluate the effect of the PCV7 on the pneumococcal single 
and multiple colonization flora of young children in Portugal, and ii) to assess the 
colonization and virulence potential of non-PCV7 serotypes using mouse models. 
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2. Effect of the seven-valent conjugate pneumococcal vaccine 
on carriage and drug resistance of Streptococcus pneumoniae 
in healthy children attending day-care centers in Lisbon. 
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2.1. Abstract 
Aims: Prospective study to evaluate the impact of the 7-valent pneumococcal conjugate 
vaccine (Prevenar) on the nasopharyngeal (NP) carriage of drug resistant Streptococcus 
pneumoniae (DRPn), by healthy children attending day-care centers (ages 6 months–6 
years). Methods: Vaccinees (238 children) who received vaccine and controls (457 
children) were followed for carriage of total S. pneumoniae and DRPn and for the 
serotypes and genetic backgrounds of DRPn during 6 consecutive sampling periods 
between May 2001 and February 2003. Results: We detected no significant differences 
between vaccinees and the control group in the total carriage rate of Pn (average, 68%) 
or in the frequency of carriage of DRPn (average, 38%), including the frequency of 
penicillin nonsusceptible strains (average, 24%). In contrast, there was a decline in the 
carriage of DRPn with vaccine serotypes, which was compensated by the appearance 
and gradual increase in the frequency of DRPn expressing unusual serotypes (6A, 10A, 
15A and 15C, 19A, 23A, 33F), which were not present in the vaccine as well as an 
increase in non typeable strains. The majority of the DRPn with unusual serotypes 
showed different pulsed-field gel electrophoresis patterns indicating replacement of the 
original resistant flora by other clonal types of drug resistant bacteria. Antibiotic 
consumption and the frequency of respiratory tract infections were similar among the 
vaccinees and controls. Conclusions: Pneumococcal vaccination did not change the 
frequency of carriage of drug resistant strains, being the initially dominant vaccine 
serotypes replaced by others expressing non vaccine serotypes. Reduction in the 
carriage of DRPn may require a combination of the conjugate vaccine and a decrease in 
antibiotic pressure. 
 
2.2. Introduction 
The main reservoir of Streptococcus pneumoniae is the nasopharynx of young children 
(Aniansson et al., 1992; Austrian, 1986). When the balance between host and pathogen 
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is disturbed, the pneumococcus (Pn) can spread to adjacent mucosal tissues to cause 
infections such as acute otitis media (AOM) and pneumonia or enter the bloodstream 
causing invasive infections such as sepsis and meningitis (Bogaert et al., 2004a). Young 
children attending day-care centers (DCCs) commonly carry pneumococci, especially 
drug resistant strains that can easily be transmitted by person-to-person contacts in the 
environment of DCCs where antibiotic use is frequent and leads to selection for resistant 
strains (Kristinsson, 1997; Munford & Murphy, 1994; Reichler et al., 1992).  
β-Lactam antibiotics have been the most commonly used antimicrobials for treatment of 
pneumococcal disease. Since the mid-1960s, the prevalence of penicillin resistant 
strains increased worldwide complicating disease management (Appelbaum, 1992) and 
providing an incentive to address prevention of pneumococcal disease through 
immunization. 
Pneumococci comprise more than 90 serotypes defined by the capsular polysaccharide 
(Hausdorff et al., 2000b). The pneumococcal conjugate vaccine, Prevenar, is a 7-valent 
formulation that includes polysaccharides of types 4, 6B, 9V, 14, 18C, 19F and 23F 
linked to the nontoxic diphtheria variant protein carrier CRM197 (7-valent pneumococcal 
conjugate vaccine). The vaccine was introduced in the United States in 2000 (CDC, 
2000) and became available in Portugal in July 2001. This conjugated protein carrier, 
CRM197, elicits a T-cell dependent response, making it immunogenic and efficacious in 
children younger than 2 years (Black et al., 2000; Eskola et al., 2001). 
In clinical trials, the conjugate vaccine induced high concentrations of serum 
anticapsular antibodies (Shinefield et al., 1999) and reduced nasopharyngeal carriage of 
serotypes included in the vaccine [vaccine types (VT)] (Dagan et al., 1996a; Dagan et 
al., 1997; Dagan & Fraser, 2000; Dagan, 2002; Dagan et al., 2002; Dagan et al., 2003). 
Conjugate vaccines are efficacious against invasive disease and modestly beneficial 
against acute otitis media (Black et al., 2000; Black & Shinefield, 2002; Eskola et al., 
2001). Antibacterial-resistant strains of pneumococci most often are serotypes included 
in the 7-valent pneumococcal conjugate vaccine (Joloba et al., 2001; Wuorimaa & 
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Kayhty, 2002). Vaccination has a direct effect on reducing carriage of drug resistant 
pneumococci (DRPn) and an indirect effect on preventing dissemination of resistant 
strains in the community (Black et al., 2001; Givon-Lavi et al., 2003; O'Brien & Dagan, 
2003). Children protected through vaccination against VT strains are more likely to carry 
non vaccine type (NVT) strains (Lipsitch, 2001). The capacity of these NVT 
pneumococci to acquire antimicrobial resistance traits and cause disease is not known. 
The purposes of our study conducted between 2001 and 2003 were to evaluate the 
impact of the 7-valent conjugate vaccine on the nasopharyngeal carriage of drug 
susceptible and drug resistant pneumococci and to evaluate the serotypes, drug 
resistance pattern and genetic backgrounds of drug resistant pneumococci colonizing 
healthy children attending DCCs in the Lisbon area of Portugal. 
 
2.3. Materials and Methods 
Population. The target population consisted of 695 healthy children 6 months-6 years 
old attending 8 DCCs in the Lisbon area of Portugal. The DCCs were selected to reflect 
the demography of the community. DCCs were divided into 2 groups: an intervention 
group (vaccinees) with 238 children in 5 DCCs; and a control group with 457 children in 
3 DCCs. Written and signed informed consent for vaccination and sampling procedures 
was obtained from parents or guardians of all participating children. The absolute 
number of samples in the intervention group from the first to the sixth sampling period 
(2003) decreased to about one-half, because every year older children who had been 
vaccinated in the first period (2001) left the DCC and consequently could not be 
followed. 
Study design. This prospective study was conducted between 2001 and 2003 (3-year 
surveillance period). The vaccination was performed in the intervention group 
(vaccinees) in May, June and November 2001. The nasopharyngeal (NP) flora of the 
vaccinees was analyzed during 6 sampling periods: in May, June and November 2001, 
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immediately before the vaccine dose administration; and afterward in February and 
November 2002 and February 2003. Children of the control group were sampled for 
pneumococcal carriage during the same sampling periods except in the second period 
(June 2001) when they were not sampled. 
Antibiotic consumption and numbers of episodes of respiratory tract infections (RTI) 
were evaluated through questionnaires filled out by parents or guardians before each 
sampling period. 
All Pn isolates were tested for antimicrobial resistance and all further characterizations 
were restricted to drug resistant S. pneumoniae (DRPn) strains. All data including 
antimicrobial consumption, frequency of RTI as well as serotype and genetic data of S. 
pneumoniae isolates were introduced into a database of special design (Silva et al., 
2003) for further analysis. 
Vaccine administration. The 7-valent pneumococcal conjugate vaccine, Prevenar, was 
provided by Wyeth Lederle Portugal (Farma), Lda. According to the specifications of the 
manufacturer, the vaccine contains 2 µg of each of the polysaccharides of serotypes 4, 
9V, 14, 18C, 19F and 23F and 4 µg of 6B coupled to the nontoxic diphtheria-toxin 
analogue CRM197
 
and absorbed on aluminum phosphate. Infants 6 –11 months of age 
received 3 vaccine doses, children 12–24 months of age received 2 doses and children 
older than 2 years received a single dose as recommended by the vaccine 
manufacturer. The 238 children enrolled in the intervention group received a total 
number of 305 doses of vaccine during the 3 vaccination periods. Intramuscular injection 
of 0.5 mL of vaccine was performed by a pediatric nurse in the deltoid muscle of the 
upper arm of each child. 
Specimen collection and identification. Sampling was performed by trained pediatric 
nurses. A single nasopharyngeal flexible swab (BBL Culture Swab; Becton-Dickinson, 
Sparks, MD) was inserted through each child’s nostril until it touched for a few seconds 
the posterior wall of the nasopharynx. The swab was removed, then introduced into the 
transport medium (Stuart medium) and transported at ambient temperature to the 
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Laboratory of Molecular Genetics at Instituto de Tecnologia Química e Biológica. 
Bacterial samples were processed within 4 hours after arrival at the laboratory as 
described previously (de Lencastre et al., 1999). Single colonies streaked on blood agar 
plates and identified as S. pneumoniae were grown in tryptic soy agar (Difco, Detroit, 
MI), and isolates were frozen and stored at -70°C ( de Lencastre et al., 1999). 
Antimicrobial susceptibility testing. All Pn strains were tested by the Kirby-Bauer 
technique, according to the National Committee for Clinical Laboratory Standards 
recommendations (NCCLS, 2000), against oxacillin, chloramphenicol, erythromycin, 
clindamycin, tetracycline, trimethoprim-sulfamethoxazole and levofloxacin (Becton-
Dickinson). Minimum inhibitory concentrations (MICs) of penicillin and ceftriaxone were 
determined by E-test (AB Biodisk, Solna, Sweden) according to the manufacturer’s 
recommendations. 
Pneumococcal strains resistant to at least one of the antimicrobial agents tested were 
designated as DRPn. DRPn (except strains resistant only to oxacillin and/or tri- 
methoprim-sulfamethoxazole) were further characterized for serotype and genetic 
background [pulsed-field gel electrophoresis (PFGE) pattern]. 
Serotyping. DRPn were serotyped by the Quellung reaction with the use of 
commercially available antisera (Statens Seruminstitut, Copenhagen, Denmark) 
(Sorensen, 1993). 
Strains that gave negative or positive reaction for agglutination with all the pooled sera 
were named non typeable (NT). Pn strains with serotypes 4, 6B, 9V, 14, 18C, 19F and 
23F, included in the vaccine, were defined as VT strains. Strains with other serotypes, 
were defined as non vaccine type (NVT) strains. 
PFGE. PFGE was performed after digestion of genomic DNA with SmaI using Pn strain 
R6 and PFGE λ marker (New England Biolabs) as molecular weight standards 
according to an earlier protocol (Sá-Leão et al., 2000b). 
Classification of PFGE patterns was performed by visual comparison according to 
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accepted criteria (Tenover et al., 1995). We compared our patterns with the ones 
identified in studies from our group conducted between 1996 and 1999 (S. Nunes et al., 
unpublished data) (Sá-Leão et al., 2000a; Sá-Leão et al., 2000b) and also with the 
patterns of 26 international clones included in the Pneumococcal Molecular 
Epidemiology Network (PMEN) (McGee et al., 2001). 
Statistical analysis. The effect of vaccination was evaluated on vaccinated and 
nonvaccinated cohorts. Contingency table analysis was conducted with the χ2 test, both 
for individual sampling periods and for the pairwise comparison of all periods. The χ2 
test was performed for association between vaccination and carriage of Pn or 
occurrence of afflictions episodes. A maximum error type I of 0.05 was considered for 
recognition of a significant vaccine effect. 
 
2.4. Results 
Demographic and clinical data. We enrolled 695 children between May 2001 and 
February 2003. There were no significant differences concerning demographic and 
clinical characteristics between the intervention group and control group. 
The intervention group (n=238) included 118 male and 120 female subjects. The control 
group (n=457) included 237 boys and 220 girls. 
Antibiotic consumption at sampling or 1 month before sampling was high in both groups 
during all sampling periods, as reported by the parents through the questionnaires. 
Twenty-eight children (4%) in the intervention group and 32 children (5%) in the control 
group had taken antibiotics at the time of sampling. One hundred and nine children 
(17%) in the intervention group and 74 children (11%) in the control group took 
antibiotics 1 month before sampling. 
Otitis media, throat infection and low respiratory infections were indicated as the 
afflictions that most frequently caused antimicrobial consumption in both groups. Forty-
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seven children (34%) in the intervention group and 40 children (29%) in the control 
group took antibiotics because of otitis media. Forty-seven children (34%) in the 
intervention group and 58 children (42%) in the control group took antibiotics because of 
throat infection. Concerning lower respiratory infection, only 9% (13 children) and 6% (9 
children) of children included, respectively, in the intervention and control groups took 
antibiotic because of this affliction. 
Carriage of S. pneumoniae strains. Of the 1,950 NP samples obtained, 1,014 were 
from children in the intervention group (vaccinees) and 936 from the control group. Total 
carriage rate of Pn strains was similar in intervention and control groups during all 
sampling periods. As many as 68% of the NP samples carried S. pneumoniae in both 
the control (633 Pn strains isolated from 936 NP samples) and the intervention (692 Pn 
strains isolated from 1,014 NP samples) groups. The greatest difference in Pn carriage 
between the 2 groups was 9% (Table 1). The carriage rate of Pn fluctuated in a very 
similar manner among controls and vaccinees during the sampling periods. 
The carriage rate of DRPn was similar in intervention and control groups throughout the 
sampling periods. Among the total of 692 Pn strains collected from the intervention 
group, 37% were DRPn; among the 633 Pn strains recovered from the control group, 
39% were DRPn (Table 1). 
Carriage rates of penicillin nonsusceptible strains were also similar and constant during 
the sampling periods and no significant differences were found between intervention and 
control groups. Of 692 Pn strains isolated in the intervention group, 24% were 
nonsusceptible to penicillin; of 633 Pn strains isolated in the control group, 23% were 
penicillin nonsusceptible (Table 1).  
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Table 1. Nasopharyngeal carriage of Streptococcus pneumoniae strains isolated 
in the Intervention and Control groups during the 6 sampling periods. 
Carriage rate 
Intervention group Control group 
NP 
Sampling 
Periods NP 
samples Pn 
strains* 
DRPn 
strains† 
PNSPn 
strains‡ 
PSPn 
strains§ 
NP 
samples Pn 
strains* 
DRPn 
strains† 
PNSPn 
strains‡ 
PSPn 
strains§ 
May 
2001, 1st 243 
182 
(75.0) || 
84 
(46.0) 
59 
(32.4) 
25 
(13.7) 233 
163 
(70.0) 
81 
(50.0) 
46 
(28.2) 
35 
(21.5) 
June 
2001, 2nd 196 
132 
(67.0) 
53 
(40.0) 
35 
(26.5) 
18 
(13.6) NA NA NA NA NA 
November 
2001, 3rd 152 
97 
(64.0) 
41 
(42.0) 
24 
(24.7) 
17 
(17.5) 214 
143 
(67.0) 
58 
(41.0) 
34 
(23.7) 
24 
(16.8) 
February 
2002, 4th 168 
105 
(63.0) 
32 
(30.5) 
18 
(17.1) 
14 
(13.3) 182 
105 
(58.0) 
31 
(29.5) 
21 
(20.0) 
10 
(9.5) 
November 
2002, 5th 128 
94 
(73.0) 
28 
(30.0) 
18 
(19.1) 
10 
(10.6) 132 
93 
(70.5) 
30 
(32.0) 
19 
(20.4) 
11 
(11.8) 
February 
2003, 6th 127 
82 
(65.0) 
21 
(26.0) 
15 
(18.2) 6 (7.3) 175 
129 
(74.0) 
49 
(38.0) 
28 
(21.7) 
21 
(16.3) 
Total 1014 692 (68.2) 
259 
(37.4) 
169 
(24.4) 
90 
(13.0) 936 
633 
(67.6) 
249 
(39.3) 
148 
(23.3) 
101 
(15.9) 
 
*Carriage of S. pneumoniae (both drug resistant and drug susceptible) as percent of NP samples 
collected. 
†
Carriage DRPn: strains resistant to any of the antimicrobial agents, alone or in combination (except 
strains only resistant to oxacillin). 
‡
Carriage PNSPn: strains nonsusceptible to penicillin (MIC ≥ 0.094 µg/mL) alone or in combination with 
other antimicrobial agents. 
§
Carriage PSPn: strains susceptible to penicillin (MIC < 0.094 µg/mL) but resistant to other antimicrobial 
agents. These numbers are derived by subtracting the numbers in column 
‡
 from the numbers in column 
†
  
( § =† - ‡ ). 
||Numbers in parentheses, percent.  
 
NA indicates data not available. 
 
Within the intervention group, a decline was observed in penicillin nonsusceptibility from 
> 24% of isolates in 2001 to 17–19% in 2002–2003, which was not observed in the 
control group, although that difference was not statistically significant (P >0.05). All 
pneumococcal strains were susceptible to levofloxacin and the overall prevalence of 
strains resistant to the other antimicrobials tested was similar between control and 
intervention samples. The differences in susceptibility to each one of the antimicrobial 
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tested between intervention and control were not statistically significant (P > 0.05) 
except for chloramphenicol (Table 2). 
 
Table 2. Streptococcus pneumoniae strains resistant to antimicrobial agents*. 
No. of DRPn 
Resistance to 
Intervention group Control group 
Penicillin 169 (24.4) † 148 (23.3) 
Erythromycin 170 (24.5) 151 (23.8) 
Clindamycin 159 (22.9) 139 (21.9) 
Tetracycline 144 (20.8) 132 (20.8) 
Trimethoprim-sulfamethoxazole 119 (17.1) 101 (15.9) 
Chloramphenicol 16 (2.3) 29 (4.5) 
Ceftriaxone 7 (1.0) 6 (1.0) 
 
*Carriage rate was calculated over the total number of Pn strains isolated in the intervention (n = 692) and 
control (n = 633) groups. 
†
Number in parentheses, percent. 
 
Serotypes of DRPn. Although the total number of DRPn strains was similar between 
the control and intervention samples, differences became apparent once the strains 
were separated into bacteria expressing VT and NVT capsular polysaccharides (Fig. 1). 
In the intervention group (vaccinees), the frequency of VT strains decreased 
significantly, from 81% to 5%, throughout the 6 sampling periods (P < 0.05). At the same 
time, the frequency of NVT strains increased significantly from 19% to 95% (P < 0.05). 
In the control group, the carriage rate of VT strains remained high (between ~59 and 
75%) and the carriage rate of NVT strains remained between 25 and 46% and showed 
no trends of consistent increase or decline during the surveillance period (Table 3 and 
Fig. 1). 
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Table 3. Serotypes of DRPn isolated in the Intervention and Control groups during 
the 6 sampling periods. 
Carriage rate of vaccine and non vaccine type DRPn strains* 
Intervention group Control group Nasopharyngeal sampling periods DRPn 
strains 
VT strains
†
 NVT strains
‡
 
DRPn 
strains 
VT strains
†
 NVT strains
‡
 
May 2001, 1st 79 64 (81.0) § 15 (19.0) 70 41 (59.0) 29 (41.0) 
June 2001, 2nd 47 32 (68.0) 15 (32.0) NA NA NA 
November 2001, 3rd 31 21 (68.0) 10 (32.0) 51 38 (75.0) 13 (25.0) 
February 2002, 4th 27 14 (52.0) 13 (48.0) 28 19 (68.0) 9 (32.0) 
November 2002, 5th 26 8 (31.0) 18 (69.0) 28 15 (54.0) 13 (46.0) 
February 2003, 6th 21 1 (5.0) 20 (95.0) 46 31 (67.0) 15 (33.0) 
Total DRPn strains 231|| 140 91 223|| 144 79 
 
*Carriage rate was calculated over the DRPn strains isolated, respectively, in the intervention or control 
groups and selected for serotyping. 
†
VT strain: strains with serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, included in the vaccine. 
‡
NVT strains: strains with other serotypes different from the ones included in the vaccine and NT strains. 
§
Numbers in parentheses, percent. 
||All DRPn strains were selected for serotyping (except strains only resistant to oxacillin and/or trimethoprim-
sulfamethoxazole). 
 
NA indicates not available. 
 
Before vaccine administration (first sampling period), the carriage rate of VT DRPn 
strains was 81% in the intervention group and 59% in the control group. During the 
remaining sampling periods, carriage rates of DRPn with vaccine serotypes continued to 
decrease in the intervention group reaching 5%; whereas the frequency of these strains 
remained above 53% in the controls. The prevalence of NVT strains in the first sampling 
period was 19% in the intervention group and 41% in the control group. 
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Figure 1. Distribution of VT and NVT strains in the Intervention (A), and Control (B) 
groups along time.    indicates VT strains with respective serotypes;   , NVT 
strains with respective serotypes. 
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Drug-resistant strains 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
1st 66. 9V . 14. 19F. 23F 6A. 15A. 15C. 33F n = 79 
2nd 66.14. 19F. 23F 6A. 15A. 33F n = 47 
3rd 6A. 15A. 15C. 19A 
4th . : lOA. 15A. 19A n = 27 
5th 66. 14. 19F, 23F lOA. 15A. 19A n = 26 
6th 15A. 19A, 23A. 33F n = 21 
Drug-resistant strains 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
1st 66. 14. 19F, 23F 6A. 15A. 19A. 33F n = 70 
2nd data not available 
3rd 6A. 17. 18. 19A n = 51 
4th . : 6A. 19A. 33F n = 28 
5th 66, 14. 23F 19A n = 28 
6th 66, 14. 19F. 23F 9A. 15A. 19A n = 46 
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During the remaining sampling periods, carriage rates of NVT strains increased in the 
intervention group, reaching 95% in the sixth sample, whereas the frequency of these 
serotypes remained on average ~33% of the DRPn strains in the control samples (Table 
3). Of all the DRPn strains with VT serotypes that were present in the first sample from 
the intervention group, a single serotype 9V remained by the final sampling period. 
DRPn strains expressed a wider range of NVT serotypes that included serotypes 6A, 
10A, 15A, 15C, 19A, 23A and 33F. Serotype 15A was recovered in all sampling periods 
(Fig. 1). In the control samples, the NVT serotypes were 6A, 9A, 15A, 17, 18, 19A and 
33F with the most frequent one being 19A (Fig. 1). NT strains were detectable in the 
intervention (25 strains) and control (28 strains) groups. 
Penicillin nonsusceptible S. pneumoniae strains expressing vaccine and non 
vaccine serotypes. Among DRPn strains, penicillin nonsusceptible strains with VTs 
decreased from 59% to 5% and NVT strains increased from 15% to 67% in the 
intervention group. In the control group, penicillin nonsusceptible strains most frequently 
expressed VT serotypes (Fig. 2). High level resistance to penicillin (MIC ≥ 1.5 µg/mL) 
was only observed in few VT isolates. Penicillin MIC50 was 0.094 µg/mL in VT isolates, 
either in the intervention or control, and among the NVT isolates it was 0.125 µg/mL in 
the intervention and 0.032 µg/mL in the control. Penicillin MIC90 was 1 µg/mL in VT 
isolates of the intervention and 0.75 µg/mL in the control; the MIC90 was 0.5 µg/mL 
among the NVT isolates of intervention and control groups. 
PFGE patterns of DRPn strains. Most of the vaccine type DRPn, either in the 
intervention (vaccinees) or control groups, belonged to 9 internationally spread epidemic 
clones identified and deposited in the collection of the PMEN (Figs. 3 and 4). These 
clonal types were as follows: Spain23F-1, Spain6B-2, Spain9V-3, England14-9, Poland6B-20, 
Portugal19F-21, Greece6B-22, Sweden15A-25 and Colombia23F-26. 
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Figure 2. Penicillin nonsusceptible strains (MIC ≥ 0.094 µg/mL) and penicillin-
susceptible strains (MIC < 0.094 µg/mL) with vaccine (VT) and non vaccine (NVT) 
serotypes in the intervention (A) and control (B) groups along time. Dashed black 
bars indicate penicillin nonsusceptible (VT) strains; dashed gray bars, penicillin 
nonsusceptible (NVT) strains; black bars, penicillin susceptible but resistant to 
other antimicrobials (VT) strains; gray bars, penicillin susceptible but resistant to 
other antimicrobials (NVT) strains. 
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Figure 3. Clonal distribution among VT and NVT strains isolated in the 
intervention (A) and control (B) groups along time. Black bars indicate VT strains 
(PMEN clonal types); gray bars, VT strains (non-PMEN clonal types); dashed black 
bars, NVT strains (PMEN clonal types); dashed gray bars, NVT strains (non-PMEN 
clonal types). 
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Figure 4. PFGE patterns identified in the study (Control and intervention). A, 
PMEN clones; B, non-PMEN clones. The λ ladder and the reference strain R6 are 
indicated and were used as molecular weight markers. Ordinate shows molecular 
sizes in kilobases. 
 
 
 
 
 
 
 
 
 
In the intervention group, during the first sampling period, 81% of the 79 DRPn isolates 
expressed VT capsules. The majority of vaccine type strains belonged to one or the 
other of 9 international epidemic clones (PMEN clones), and only 3 VT strains showed 
PFGE types different from the PMEN clones. The rest of the 15 DRPn from this 
sampling period expressed NVT capsules: 5 strains belonged to the serotype 15A clone 
of Sweden15A-25; and 6 of the other 10 strains showed 4 non-PMEN clonal types. 
In this period, epidemic PMEN clonal types were dominant over the non-PMEN clonal 
types. Of 79 DRPn strains isolated, 89% (70 strains) belonged to 8 epidemic PMEN 
clonal types and 11% only (9 strains) belonged to 7 non-PMEN clonal types. By the last 
sampling period, the number of VT strains in the intervention group was reduced to a 
single serotype 9V strain with the PFGE pattern of the international clone Spain9V-3. All 
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the rest of the 20 DRPn expressed NVT capsules and were represented by 7 PFGE 
patterns of which only 1 is a PMEN clone. In this last period, the non-PMEN clones 
became dominant over the epidemic PMEN clones. Of 21 DRPn strains isolated, 2 
strains (10%) belonged to PMEN clonal types (2 clones) and 19 strains (90%) belonged 
to 7 non-PMEN clonal types. 
In the control group during the first sampling period, when the majority (41 of 70) of 
DRPn strains expressed VT capsules, all of these belonged to 7 internationally spread 
clones identified in the PMEN. The representation of these internationally spread 
epidemic clones remained high among the DRPn strains with VT capsular types 
collected throughout the sampling periods. 
The epidemic PMEN clonal types were dominant over the non-PMEN clonal types in the 
first period. Of 70 DRPn strains isolated, 84% (59 strains) belonged to 8 epidemic 
PMEN clonal types and 16% (11 strains) belonged to 8 non-PMEN clonal types. By the 
last sampling period, PMEN clonal types and non-PMEN clones were detected in similar 
ratios, concerning both the number of clonal types and the number of strains. Of 45 
DRPn strains isolated, 49% (22 strains) belonged to PMEN clonal types (8 clones) and 
51% (23 strains) belonged to 12 non-PMEN clonal types. 
In summary, of 231 DRPn strains from the intervention group, 71% (165 strains) had 
PFGE patterns identical with those of 9 international clones included in the PMEN 
(McGee et al., 2001). The remaining 66 strains (29%) presented 19 different PFGE 
patterns (non-PMEN clones). In the control group, 143 of 222 DRPn strains (64%) had 
PFGE patterns identical with those of 8 international clones included in the PMEN 
(McGee et al., 2001). The remaining 79 strains (36%) presented 29 different PFGE 
patterns (non-PMEN clones). 
Serotyping and molecular typing by PFGE identified a few cases that might represent 
capsular transformation. Among the isolates recovered from the control group at the first 
sampling period, 6 strains showed the PFGE pattern of the international clone Spain23F-
1 that typically expresses serotype 23F capsule. These particular 6 strains expressed 
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serotype 19A. Another group of 10 strains showed the PFGE pattern of the international 
clone Poland6B-20, which typically expresses serotype 6B. The 10 particular strains 
expressed serotype 6A. Additional examples for putative capsular switch were also 
detected among some strains with familiar PFGE type but expressing no identifiable 
capsular types (non typeable strains). There was no evidence for an increased 
frequency of strains with such suspected capsular changes among the DRPn isolated 
from the nasopharyngeal samples of vaccinees. Therefore capsular switch did not 
appear to be a major mechanism contributing to the change from the vaccine to the non 
vaccine serotype of the DRPn isolates. 
 
2.5. Discussion 
We evaluated the impact of the 7-valent pneumococcal vaccine on the carriage of drug 
resistant S. pneumoniae strains in the nasopharynx of children attending DCCs in 
Portugal. Because most drug resistant pneumococci express a limited number of 
serotypes that are present in the 7-valent vaccine, the carriage rates of drug resistant 
pneumococci was expected to decrease in the vaccinees as part of the reduction in all 
pneumococcal VTs that colonized the nasopharynx of the children. 
In agreement with several studies on the impact of pneumococcal conjugate vaccines, 
our results also showed that vaccination with 7-valent pneumococcal vaccine did not 
affect the global carriage of Pn strains (susceptible and resistant). Also in agreement 
with previous studies (Dagan et al., 1996a; Dagan et al., 1997; Dagan, 2002; Dagan et 
al., 2002; Dagan et al., 2003), the carriage of vaccine type DRPn strains decreased 
markedly from 81% to 5% in the vaccinated children. In contrast to findings reported in 
some earlier studies (Dagan et al., 1996a; Dagan et al., 1997; Dagan, 2002; Dagan et 
al., 2002; Dagan et al., 2003; Klugman, 2001; Piffer, 2002), the total carriage rate of 
DRPn was not reduced. In parallel with the decline in the frequency of DRPn expressing 
the vaccine serotypes, there was an increase in DRPn with non vaccine serotypes. As a 
result, the carriage rate of DRPn strains has remained virtually unchanged during the 3 
years of follow-up sampling of the NP flora of vaccinees. Furthermore the DRPn with the 
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non vaccine serotypes were represented in almost all cases by bacteria exhibiting 
genetic backgrounds different from the PMEN clones, as identified by their unusual 
PFGE patterns. 
We explain the replacement of vaccine type DRPn by drug resistant pneumococci with 
different genetic backgrounds and expressing NVT serotypes as the combined effect of 
vaccine pressure and undiminished use of antibacterial agents. Vaccination against the 
VT serotypes must exert selective pressure on the colonizing flora of pneumococci 
preventing the cross-infection and multiplication of the vaccine type strains, which 
provides a competitive advantage to pneumococci expressing other capsular types not 
present in the vaccine. The emergence of drug resistant strains among these NVT type 
bacteria could be because of the acquisition of drug resistant determinants from the 
DRPn strains with the VT capsules that are receding under the vaccine pressure. 
Alternatively drug resistant strains with the NVT capsules may preexist as minor 
components of the nasopharyngeal flora because of multiple carriage of pneumococci 
(Sá-Leão et al., 2002). This latter alternative appears likely given that DRPn with 
serotypes 6A, 15A, 15C and 33F were identified in the NP flora at the onset of the study. 
Vaccine efficacy is closely linked to a decrease in vaccine type strains that normally 
implies a decrease in resistance and virulence (Joloba et al., 2001; Wuorimaa & Kayhty, 
2002). Drug resistance, especially to penicillin, is found almost exclusively among 
isolates of the vaccine serotypes (Klugman, 2001; Wuorimaa & Kayhty, 2002). In our 
study, we found that penicillin nonsusceptible strains with non vaccine serotypes 
became frequent in vaccinees with time (Fig. 2). Our findings are consistent with the 
predictions of mathematical modeling studies suggesting that the probability for the 
occurrence of long term replacement of DRPn would increase after vaccination (Temime 
et al., 2004). 
The pathogenic potential of non vaccine serotypes is not known, although the capacity 
of these strains for effective colonization might imply pathogenic potential (Hava & 
Camilli, 2002). This has been shown by the Finnish Otitis Media Study Group (Eskola et 
al., 2001), who found a 33% increase in AOM episodes caused by NVT in a group of 
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vaccinated children. In our study, non vaccine serotypes isolated from vaccinees 
became prominent in the nasopharynx (95%) with some serotypes (e.g., 15A, 33F) 
repeatedly recovered from children along the sampling periods (Fig. 1). High frequency 
and prolonged duration of carriage has been associated with frequent pneumococcal 
disease (Smith et al., 1993). The serogroups and serotypes identified in our study, such 
as 6A, 10A, 15A/C, 19A, 23A and 33F, have been associated with AOM episodes in 
Finland, the United States and Israel (Eskola et al., 2001; McEllistrem et al., 2003; Porat 
et al., 2004) and with invasive disease episodes in France (6A, 10A, 15C, 19A) (Doit et 
al., 2002), United Kingdom (6A, 15C, 19A, 33F) (Brueggemann et al., 2003) and 
Portugal (6A, 10A, 19A, 23A, 33F) (Serrano et al., 2004). 
The nasopharyngeal flora of DRPn of vaccinated children in our setting appeared to 
undergo a progressive compositional change over time because of replacement of the 
initially dominant epidemic DRPn clones by other clonal types of pneumococci 
expressing new serotypes that are not present in the vaccine. 
The origin and nature of resistance determinants and pathogenic potential of the DRPn 
clones replacing the vaccine type pneumococci in the nasopharyngeal flora are 
unknown. However, the results of our study seem to imply that reduction of the carriage 
of drug resistant strains of S. pneumoniae requires a combination of the conjugate 
vaccine and reduction in the use of antimicrobial agents. 
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3.1. Abstract 
The impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on the 
pneumococcal flora has been mostly studied without evaluating multiple colonization 
and the mechanism(s) leading to serotype replacement. These issues are addressed 
here, while assessing the effect of a single PCV7 dose. A group of children received one 
PCV7 dose just after nasopharyngeal sampling, with the control receiving no vaccine 
and both groups being sampled again a month later. Up to 10 pneumococcal isolates 
were recovered per colonized child — 1,224 isolates were serotyped and representative 
ones characterized by pulsed-field gel electrophoresis. In vaccinated children, serotype 
replacement between vaccine (VT) and non vaccine (NVT) types occurred in single and 
multiple carriers, and VTs were less prone to be de novo acquired. NVT unmasking was 
only detected in the vaccinated group. One month after vaccination with a single dose, 
PCV7 prevents VT de novo acquisition and promotes NVT unmasking. 
 
3.2. Introduction 
Streptococcus pneumoniae remains one of the most important human pathogens in our 
era, together with malaria, TB and HIV (WHO, 1999). The primary ecological reservoir of 
S. pneumoniae is the nasopharynx of young children who are colonized 
asymptomatically early in life (Gray et al., 1980). When the balance between host and 
pathogen is disturbed, the nasopharynx can become a launching pad for pneumococcal 
disease. Colonizing pneumococci may spread to adjacent mucosal tissues to cause 
infections such as acute otitis media and pneumonia, or enter the bloodstream causing 
invasive infections such as sepsis and meningitis (Bogaert et al., 2004a; Faden et al., 
1997). The first two years of life are the period of greatest risk for pneumococcal disease 
(Gray et al., 1979), and methods that could suppress nasopharyngeal colonization by 
disease-causing pneumococci are believed to represent means of preventing or 
decreasing the frequency of pneumococcal infections.  
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The majority of pneumococci causing life-threatening disease in children in the USA, 
and to a certain extent also in Europe, express on their surface seven chemically 
different capsular types (vaccine types — VT), which are included in the 7-valent 
pneumococcal conjugate vaccine (PCV7) (Black et al., 2000). Several surveillance and 
randomized controlled studies have shown that routine vaccination with PCV7 is 
efficacious against VT pneumococcal invasive disease in children younger than 2 years 
old (Black et al., 2000; CDC, 2005; O'Brien et al., 2003; Whitney et al., 2003). 
Concerning pneumococcal colonization, the foremost conclusion of several studies is 
that PCV7 reduces nasopharyngeal carriage of VT pneumococci but, in parallel, there is 
an increase in non vaccine type (NVT) carriage, a phenomenon termed serotype 
replacement carriage (Dagan et al., 1996a; Dagan, 2002; Frazão et al., 2005; Sá-Leão 
et al., 2009). 
Traditionally, the most common method used to study the pneumococcal colonizing flora 
has been the serotyping of a single isolate recovered from the nasopharynx of each 
individual carrier. However, studies have shown that most individuals carry 
simultaneously more than one pneumococcal isolate (co-colonization), which can differ 
in properties such as serotype and genotype (Gray et al., 1980; Sá-Leão et al., 2002). 
Characterizing a single isolate does not allow detection of qualitative and quantitative 
changes that may occur in the nasopharyngeal flora under the influence of strong 
selective pressures, such as conjugate pneumococcal vaccines. In order to overcome 
this problem, in the colonization study described here we serotyped up to ten isolates 
per child, selecting randomly and/or by isolate morphology in cases where 
morphological differences were apparent. Until consensus on a more suitable method 
for the evaluation of the nasopharyngeal flora of pneumococci is reached, a recent study 
proposed serotyping of multiple isolates selected on the basis of morphological variation 
plus random picking as a reasonable way of assessing the composition of the 
pneumococcal nasopharyngeal flora (Hare et al., 2008). 
The World Health Organization and UNICEF have recognized the safety and 
effectiveness of PCV7, recommending the inclusion of this vaccine in national 
immunization programs. Indeed, 35 high- and middle-income countries currently provide 
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routine childhood immunization against pneumococcal disease, and Rwanda has 
recently become the first developing nation to introduce PCV7 (Rowland et al., April 
2009). However, in developing countries the current high price of the vaccine doses 
hinders the introduction of PCV7 (ACIP, 2000). There are reasons to believe that a 
single PCV7 dose has the potential to prevent a significant amount of invasive 
pneumococcal disease in children (Barzilay et al., 2006; Whitney et al., 2006). As the 
nasopharynx is the launching pad for pneumococcal disease, it is also of utmost 
importance to understand the effect of one dose in this niche. If proven efficacious, the 
use of a single vaccine dose may reduce the cost of vaccination sufficiently to facilitate 
introduction of PCV7 in more developing countries. To our best knowledge, the efficacy 
of a single dose of PCV7 on single and multiple colonization has not been evaluated, 
and studies on the effect of fewer than the recommended doses are scarce (Jones et 
al., 2005; Revai et al., 2006; van Gils et al., 2009; van Kempen et al., 2006). This 
evaluation should rely not only on the pneumococcal prevalence comparison among 
vaccinated and control groups, but also on the identification of the actual mechanism of 
the vaccine’s effect (Rinta-Kokko et al., 2009).  
In this study we evaluated the impact of one PCV7 dose on single and multiple 
pneumococcal colonization in a group of children attending day-care centers, identifying 
the mechanisms of the vaccine’s effect.  
 
3.3. Materials and Methods 
Study population. Eighty-five healthy children attending 5 day-care centers in the 
Lisbon area of Portugal were enrolled in this observational study of the effect of a single 
dose of PCV7 on pneumococcal colonization. 
Vaccinated and control group allocation was based on three criteria — age between 12 
and 24 months, same geographical area, and same social background. Children fulfilling 
the three requirements were included in the study. Those that were immunized with a 
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single PCV7 dose (69 children) constituted the vaccinated group, and those that 
received no vaccine (16 children) formed the control group. 
In the vaccinated group, 38 children (55%) were males and 31 (45%) were females. In 
the control, seven children (44%) were males and nine (56%) were females. 
Written and signed informed consent was obtained from parents or guardians of 
participating children for vaccination and sampling procedures.  
Vaccine administration. PCV7 was provided by Wyeth Lederle Portugal (Farma), Lda. 
The vaccinated group was immunized with a single dose of the vaccine in May 2001. 
The intramuscular injection of 0.5 mL of vaccine was performed by a pediatric nurse in 
the deltoid muscle of the upper arm of each child. 
Specimen collection. Pediatric nurses collected the nasopharyngeal specimens by use 
of calcium alginate swabs (BBL Culture Swab; Becton-Dickinson, Sparks MD). Swabs 
were inserted through the child’s nostril until they touched the posterior nasopharynx, 
rotated 180 degrees, removed, placed in transport media (Stuart medium) and 
transported at room temperature to the Laboratory of Molecular Genetics at Instituto de 
Tecnologia Química e Biológica. Bacterial samples were processed within 4 h of 
collection (de Lencastre et al., 1999). 
Study design. Each child from the vaccinated and control groups was sampled in May 
and June 2001. In the vaccinated group, the first nasopharyngeal sample was collected 
immediately before immunization with a single PCV7 dose, in May 2001.  
Nomenclature definitions. Children carrying pneumococcal isolates expressing only 
one capsular type (serotype) were designated as single carriers and children carrying 
more than one serotype were designated as multiple carriers. Among the latter, the 
serotype found in the majority of the isolates (>50%) was designated as the dominant 
serotype and the remaining serotypes were named minor serotypes. The ecological 
mechanisms that could be identified in this study were defined as follows: (i) clearance 
(disappearance of a pneumococcal isolate of a given serotype); (ii) de novo acquisition 
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(acquisition of a new pneumococcal isolate of a given serotype); (iii) unmasking 
(expansion of a minor serotype that becomes the dominant serotype); (iv) maintenance 
(maintenance of a given serotype) and (v) capsular switch (an isolate maintains its 
genotype/PFGE pattern, but presents a different serotype). 
Pneumococcal isolation procedures. Each nasopharyngeal swab was streaked onto 
5 µg/mL gentamicin-5% sheep blood triptic soy agar plate and incubated at 37°C in 5% 
CO2 atmosphere. Whenever available, up to 10 pneumococcal colonies were picked 
from this primary plate. Colonies were chosen randomly and any morphologically distinct 
colony was also picked. Colonies were re-streaked and cultivated on 5% sheep blood 
triptic soy agar and frozen at -80°C in Mueller-Hin ton broth containing 15% glycerol 
(v/v). Phenotypic characteristics (optochin susceptibility, morphology, and α-hemolysis) 
were used for presumptive pneumococci identification. The bile solubility assay was 
performed on suspected pneumococcal cultures exhibiting decreased susceptibility to 
optochin. These purified cultures were used in the subsequent assays. 
Serotyping. All pneumococcal isolates were serotyped by the Quellung reaction using 
specific capsular antisera (Statens Seruminstitut, Copenhagen, Denmark) (Sorensen, 
1993). Distinction between serotypes 6A and 6C was achieved by PCR using previously 
described primers (Park et al., 2007a). Capsular types targeted by PCV7 (4, 6B, 9V, 14, 
18C, 19F, and 23F) were classified as VT. Isolates expressing capsular types not 
included in PCV7 and non typeable isolates were classified as NVT. 
Pulsed-field gel electrophoresis (PFGE). PFGE was performed according to a 
previously described protocol (Sá-Leão et al., 2000b) after digestion of total DNA with 
SmaI (New England Biolabs) using as molecular weight standards the pneumococcal 
isolate R6 and the PFGE λ marker (New England Biolabs). In order to screen for 
putative capsular switch events, PFGE patterns of representative isolates were 
compared. To this end, one isolate for each serotype observed in a given child per 
sampling period was randomly selected. 
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Statistical analysis. Analysis of association between vaccination state and 
pneumococcal colonization was performed by calculating the odds ratio (OR), and 
statistical significance was assessed with χ2 test or Fisher’s exact test when appropriate. 
A maximum type I error of 0.05 was considered for recognition of a significant 
vaccination effect. 
 
3.4. Results 
All children of the vaccinated and control groups enrolled in this study yielded two 
nasopharyngeal swabs, the first in May 2001 and the second in June 2001. The average 
number of isolates per swab was 9 (range, 1-10) and the mode was 10. Overall, we 
isolated and serotyped 1,224 pneumococci, and the PFGE profile for representative 
isolates of each serotype was determined. 
Prevalence of carrier children and pneumococcal isolates. In both the vaccinated 
and control groups the overall prevalence of single and multiple carrier children, as well 
as the number of pneumococcal isolates, was similar (P > 0.05) in the two sampling 
periods (Table 1). 
Prevalence of VT and NVT isolates in single carriers. Regarding the vaccinated 
group, in May 2001 (pre-vaccine sampling period), among the 430 pneumococcal 
isolates recovered from single carriers, 13 serotypes were identified although four VT 
serotypes (6B, 14, 19F, and 23F) accounted for the majority of the isolates (60%) (Table 
2). In June 2001, 1 month after vaccination with a single PCV7 dose, 14 serotypes were 
identified among the 430 pneumococcal isolates recovered. The frequency of VT 
serotypes decreased from 60 to 39%, while the frequency of NVT isolates increased 
from 40 to 61% (P < 0.001) (Table 2). Concerning the control group, in May 2001, 
among the 110 pneumococcal isolates recovered from single carriers, five serotypes 
were identified of which three VT serotypes (6B, 19F, and 23F) accounted for the 
majority of the isolates (64%) (Table 2). In June 2001, six serotypes were identified 
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among the 100 pneumococcal isolates recovered. The frequency of VT serotypes (6B, 
14, 19F, and 23F) increased from 64 to 70%, while the frequency of NVT isolates 
decreased from 36 to 30% (P = 0.328) (Table 2). 
Prevalence of VT and NVT isolates in multiple carriers. In the vaccinated group, 
among the 65 pneumococcal isolates recovered from multiple carriers in May 2001 (pre-
vaccine), 10 serotypes were identified, of which four VT serotypes (6B, 14, 19F, and 
23F) represented 45% of the isolates (Table 3). In June 2001, one month after the single 
dose, nine serotypes were identified among the 59 pneumococcal isolates, with VT 
serotypes (6B, 14, and 19F) decreasing from 45 to 19%, while NVT isolates increased 
from 55 to 81% (P = 0.002) (Table 3). In the control group, among the 20 pneumococcal 
isolates recovered from multiple carriers during May 2001, four serotypes were 
identified, of which VT serotypes (6B, 19F, and 23F) represented 95% of the isolates 
(Table 3). In June 2001, two serotypes were identified among the 10 pneumococcal 
isolates, with VT serotypes increasing from 95 to 100%, while NVT isolates decreased 
from 5 to 0% (P = 1) (Table 3). 
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Table 1. Children and pneumococcal isolates of the vaccinated and control 
groups. 
No. of children (%)  No. of pneumococcal isolates (%) 
Carriage status 
May 2001 June 2001  p-Value  May 2001 June 2001 
 
p-Value 
Vaccinated group 
         
 Single carriers (1 serotype) 48 (70) 48 (70)  1a  430 (87) 430 (88)  0.896a 
 Multiple carriers (2 serotypes) 5 (7) 4 (6)  46 (9) 39 (8) 
 Multiple carriers (3 serotypes) 2 (3) 2 (3)  
1b 
 19 (4) 20 (4)  
0.657a 
 Non carriers 14 (20) 15 (21)  0.865a  0 (0) 0 (0)  - 
 Total 69 (100) 69 (100)  -  495 (100) 489 (100)  - 
Control group 
         
 Single carriers (1 serotype) 11 (69) 10 (63)  1b  110 (85) 100 (91)  0.704a 
 Multiple carriers (2 serotypes) 1 (6) 1 (6)  10 (8) 10 (9) 
 Multiple carriers (3 serotypes) 1 (6) 0 (0)  
1b 
 10 (8) 0 (0)  
0.193a 
 Non carriers 3 (19) 5 (31)  1b  0 (0) 0 (0)  - 
 
Total 16 (100) 16 (100)  -  130 (100) 110 (100)  - 
aχ2 test; . 
bFisher exact test. 
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Table 2. Serotypes found among pneumococcal isolates from single carriers of 
the vaccinated and control groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 p-Value < 0.001 by χ2 test. 
b
 p-Value = 0.328 by χ2 test. 
No. of pneumococcal isolates (%) 
  
May 2001 (%) June 2001 (%) 
Vaccinated group 
        
Vaccine types 
    
6B 54 (13) 50 (11.6) 
14 53 (12) 37 (8.6) 
19F 61 (14) 60 (14) 
23F 88 (21) 22 (5.1) 
Sub-total 256 (60)a 169 (39)a 
Non vaccine types 
    
6A 20 (5) 30 (7) 
7F 20 (5) 0 (0) 
11A 20 (5) 49 (11.4) 
15A 50 (12) 30 (7) 
15B/C 10 (2) 17 (4) 
16F 23 (5) 31 (7.2) 
21 10 (1) 0 (0) 
23A 0 (0) 10 (2.3) 
23B 0 (0) 10 (2.3) 
33F 10 (2) 20 (4.7) 
38 0 (0) 20 (4.7) 
NT 11 (3) 44 (10.2) 
Sub-total 169 (40)a 261 (61)a 
Total 430 (100) 430 (100) 
Control group 
        
Vaccine types 
    
6B 30 (27.5) 20 (20) 
14 0 (0) 30 (30) 
19F 10 (9) 10 (10) 
23F 30 (27.5) 10 (10) 
Sub-total 70 (64)b 70 (70)b 
Non vaccine types 
    
6A 20 (18) 20 (20) 
19A 20 (18) 10 (10) 
Sub-total 40 (36)b 30 (30)b 
Total 110 (100) 100 (100) 
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Table 3. Serotypes found among pneumococcal isolates from multiple carriers of 
the vaccinated and control groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 p-Value = 0.002 by χ2 test. 
b
 p-Value = 1 by Fisher exact test. 
No. of pneumococcal isolates (%) 
  
May 2001 (%) June 2001 (%) 
Vaccinated group 
        
Vaccine types 
    
6B 8 (12.3) 5 (9) 
14 5 (7.7) 4 (7) 
19F 10 (15.4) 2 (3) 
23F 6 (9.2) 0 (0) 
Sub-total 29 (45)a 11 (19)a 
Non vaccine types 
    
6A 15 (23) 14 (24) 
11A 0 (0) 8 (14) 
16F 0 (0) 12 (20) 
17F 1 (1) 6 (10) 
19A 2 (3) 0 (0) 
23B 3 (5) 0 (0) 
33F 9 (14) 1 (1) 
38 6 (9) 0 (0) 
NT 0 (0) 7 (12) 
Sub-total 36 (55)a 48 (81)a 
Total 65 (100) 59 (100) 
Control group 
        
Vaccine types 
    
6B 9 (45) 0 (0) 
19F 7 (35) 2 (20) 
23F 3 (15) 8 (80) 
Sub-total 19 (95)b 10 (100)b 
Non vaccine types 
    
7F 1 (5) 0 (0) 
Sub-total 1 (5)b 0 (0)b 
Total 20 (100) 10 (100) 
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VT and NVT co-colonization condition. Among the vaccinated group, in May 2001, 
co-colonization with VT isolates was detected in five out of seven multiple carriers, of 
which four presented the VT as the dominant serotype. In June 2001, co-colonization 
with VT isolates was detected in four out of six multiple carriers, with the VT being 
identified always as a minor serotype (Fig. 1, children A to K). Regarding the control, in 
May 2001, co-colonization with VT isolates was detected in two children who presented 
VTs as the dominant serotypes. In June 2001, co-colonization was detected only once 
and two VT serotypes were found in association (23F – dominant serotype; 19F – minor 
serotype) (Fig. 1, children L and M). Serotype 6A was the most common serotype found 
among multiple carriers — it was found co-colonizing with 19F (three occasions), 6B 
(two occasions), and 14, 19A and non typeable isolates (one occasion). 
Comparison of PFGE profiles. Overall we compared 174 PFGE profiles of 
representative isolates of each of the serotypes found among the vaccinated (124 
isolates) and control (50 isolates) groups and no capsular switch phenomenon was 
detected. In the group where the vaccine pressure was present, no vaccine escapee 
recombinant isolate was observed and the NVT PFGE profiles were found to differ from 
the preceding VT serotypes. A few examples of the PFGE profiles analyzed are shown 
in Figure 2. 
Ecological mechanism of the vaccine’s effect. By observing the colonization pattern 
change from May to June 2001 among children of the vaccinated and control groups, we 
were able to assess the number of isolates that were cleared, de novo acquired, 
unmasked or maintained (Fig. 3). 
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Figure 1. Serotype associations found in the vaccinated and control groups. 
Vaccine types are represented in red and non vaccine types or non carriage in 
black. Between parentheses is the number of pneumococcal isolates per 
serotype. Children A through K are from the vaccinated group, L and M are from 
the control group. 
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Figure 2. Examples of pulsed-field gel electrophoresis profiles found among 
children of the vaccinated group in May and June 2001. Children A, B, C and D are 
the same as in Figure 1. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Examples of colonization pattern changes and respective ecological 
mechanisms. Red and black circles represent a given vaccine type (VT) or non 
vaccine type (NVT) pneumococcal isolate, respectively. Children N through Q are 
single carriers, child D is the same multiple carrier of Figure 1. 
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Table 4. Ecological mechanisms of the vaccine’s effect. 
Bearing in mind that PCV7 targets directly VT and 
indirectly NVT isolates, the effect of the vaccine on 
pneumococcal carriage was explored based on three 
potential mechanisms: prevention of VT de novo 
acquisition, enhancement of VT clearance, and 
enhancement of NVT unmasking. We compared 
these three mechanisms capable of affecting 
pneumococcal colonization between vaccinated and 
control groups to identify those that could explain the 
vaccine’s effect. 
Serotype clearance was similar between VT and 
NVT isolates among the vaccinated and control 
groups (P = 0.635). VT and NVT isolates were 
equally probable to be cleared in both groups (OR, 
1.12; 95% confidence interval (CI), 0.68-1.84) (Table 
4). De novo acquisition of VT isolates was drastically 
lower in the vaccinated group (34%) when compared 
with the control (67%). VT isolates were almost five 
times less likely to be acquired de novo in the 
vaccinated than in the control group (OR, 4.80; 95% 
CI, 2.81-8.24) (Table 4). Unmasking of NVTs was 
inexistent in the control and reached 100% in the 
vaccinated group (P < 0.001) (Table 4). 
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3.5. Discussion 
Epidemiological studies in numerous countries have demonstrated the replacement of 
VT by NVT isolates in the nasopharynx of children immunized with a multi-valent 
pneumococcal conjugate vaccine (Cohen et al., 2006; Dagan, 2002; Finkelstein et al., 
2003; Frazão et al., 2005; O'Brien et al., 2007; Sá-Leão et al., 2009). The nasopharynx 
is the immediate source of disease-causing pneumococci and the appearance of NVT 
isolates with pathogenic potential has raised concerns (Gonzalez et al., 2006; Pai et al., 
2005). In 2006, Barzilay et al. reported a 62% reduction in invasive pneumococcal 
disease caused by vaccine types in children immunized with a single PCV7 dose at 5-8 
months of age (Barzilay et al., 2006). In the same year, a matched case-control study 
observed a 93% effectiveness of a single PCV7 dose in children vaccinated at 12-23 
months of age (Whitney et al., 2006). However, the effect on nasopharyngeal 
colonization — the launching pad for pneumococcal disease — was not assessed.  
The present study evaluated the effect of a single dose of PCV7 on the nasopharyngeal 
carriage of pneumococci in day-care center attendees in Lisbon, Portugal, i.e., a study 
population in which the pneumococcal carriage rates are known to be high (Cherian et 
al., 1994; Dagan et al., 1996b; Levine et al., 1999; Takala et al., 1995). Immunized 
children in this study were between 12 and 24 months, an age at which a single dose 
showed 93% effectiveness regarding invasive disease caused by vaccine types 
(Whitney et al., 2006). Multiple pneumococcal isolates were analyzed, enabling the 
study of ecological phenomena that contribute to the serotype changes in the 
nasopharynx. 
At the population level, although the overall number of pneumococcal isolates from 
single and multiple carriers was similar in both sampling periods in the vaccinated and 
control groups (Table 1), differences became apparent once the isolates were divided 
into VTs and NVTs. In the vaccinated group, within a month, a single PCV7 dose led to 
a serotype replacement phenomenon between VT and NVT isolates, both in single and 
multiple carriers, in contrast to the control where no replacement phenomenon was 
detected (Table 2 and 3). 
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At the individual level, a serotype replacement event could also be observed. After 
vaccination with a single dose, with the exception of two children, VT isolates were not 
present or were found as minor serotypes and, in parallel, NVTs were detected as 
dominant serotypes (Fig. 1, children A to K). 
We show that a serotype replacement phenomenon took place one month after a single 
dose of PCV7, not only at the population but also at the individual level where vaccine 
types became minor serotypes co-colonizing with the emergent NVTs. Competition 
between serotypes in vaccinated children leads to serotype replacement of VT by NVT 
serotypes (Auranen et al., 2010). The rise of NVT serotypes in colonization raises 
concern, particularly among children with underlying medical conditions, as they can 
indeed become disease agents rendering disease replacement a reality (Dagan, 2009). 
Based on PFGE profile analyses, no capsular switch events were detected and thus no 
evidence was found in our study of vaccine escape recombinant isolates as reported by 
Bruegemann et al. in 2007 (Brueggemann et al., 2007). However, it should be noted that 
the failure to detect capsular switch events could be linked to the relatively small sample 
size of 174 PFGE profiles.  
In the present study, besides the pneumococcal prevalence comparisons that allowed 
detection of the known serotype replacement phenomenon between VT and NVT 
isolates (Tables 2 and 3), we actually identified the mechanism of the vaccine’s effect in 
our setting. We show that within a month, in children aged between 12 and 24 months, a 
single dose of PCV7 decreases VT colonization as it prevents de novo acquisition, and 
conversely increases NVT colonization, namely by enhancing NVT unmasking (Table 4). 
Our data is in accordance with previous studies, which suggest that conjugate vaccines 
reduce VT carriage by preventing de novo acquisition rather than clearance (Bogaert et 
al., 2004b; Dagan et al., 2003; Klugman, 2001; Whitney et al., 2006). Besides this major 
mechanism of the vaccine’s effect we propose that an additional one is the 
enhancement of NVT unmasking (Table 4). Assessment of this last mechanism was 
only possible due to the study of multiple colonization. 
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As a result of the paucity of multiple carriers, we were unable to conclude about a 
specific tendency of serotype associations before and after a single vaccine dose. 
Nevertheless, we found that 13 serotypes (6A, 6B, 7F, 11A, 14, 16F, 17F, 19A, 19F, 
23B, 23F, 33F, and 38) and non typeable isolates were able to co-colonize, associating 
with other serotypes in the children’s nasopharynx. In the vaccinated group, serotype 6A 
was the most common serotype observed among multiple carriers. Worthy of note is the 
fact that in the PCV7 era, the nasopharynx of multiple carriers can constitute a reservoir 
for VT isolates. Some VTs (e.g., 6B, 14 and 19F) prevailed as minor serotypes “masked” 
by the dominant NVT isolates, in opposition to what occurred in the control. Whether or 
not the preferred co-existence of some serotypes reflects similarity of their chemical 
structures, similar nutritional requirements and/or bacteriocin compatibility (Dawid et al., 
2007) of the particular isolates remains to be determined. 
In summary, the present study demonstrates that, as early as 1 month after vaccination 
with a single dose, PCV7 causes serotype replacement of VT by NVT isolates in single 
and multiple carriers, with the mechanisms of the vaccine’s effect being the prevention 
of VT de novo acquisition and enhancement of NVT unmasking. In the PCV7 era, the 
assessment of nasopharyngeal changes among single and multiple carriers, together 
with insight on the mechanism of the vaccine’s effect and information on pneumococcal 
virulence, will open new avenues to anticipate the long-term effect of pneumococcal 
conjugate vaccines on colonization and potentially prevent pneumococcal disease. 
Epidemiological studies accounting for multiple colonization can provide a more precise 
picture of the serotypes colonizing the nasopharynx, which can then be tested in 
developing animal models. This approach may help predict the virulence potential of 
these serotypes for their inclusion in pneumococcal vaccines even before they become 
major disease agents in humans. 
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4.1. Abstract 
The first step for Streptococcus pneumoniae disease is the establishment of 
colonization. Using epidemiological studies to identify the major serotypes selected by 
the 7-valent pneumococcal conjugate vaccine (PCV7) in the nasopharynx of children is 
of utmost importance as this provides an indicator of the future pneumococcal disease 
causing serotypes. 
The more prevalent and drug resistant non-PCV7 serotypes (6A-ST2191, 15A-ST63 and 
19A-ST276) isolated from the nasopharynx of vaccinated children in Portugal were 
tested in mouse models to mimic colonization and predict virulence potential. Steady 
colonization with 6A, 15A and 19A serotypes was found to result in the invasion and 
infection of adjacent tissues, such as the olfactory bulbs, brain, lungs and the middle ear 
mucosa. If high bacterial concentrations were introduced into the lung, all the non-PCV7 
serotypes were lethal. Serotype 19A-ST276 was the only strain to show propensity to 
cause blood infection. Experiments with laboratory-generated type 3 capsular 
transformants of the NVT strains 6A and 19A indicate that: i) colonization ability seems 
to depend not only on the capsular type, but also on the genetic background, and ii) the 
capsular type 3 has a major virulence enhancing effect, which is not dependent upon the 
genetic background of 6A and 19A parental strains. 
 
4.2. Introduction 
The first step for Streptococcus pneumoniae disease is the establishment of 
colonization, i.e., the creation of the carrier state, which can occur in over 70% of young 
children (Mato et al., 2005). Worldwide, and particularly in developing countries, 
pneumococcal disease causes significant morbidity and mortality among children 
(Greenwood et al., 2007; Mulholland, 2007). A recent report showed that S. pneumoniae 
causes around 11% of all deaths in children aged under 5 years old (O'Brien et al., 
2009). The spectrum of pneumococcal disease can range from non-invasive, mucosal 
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disease such as otitis media to severe, invasive infections such as sepsis (blood stream 
infection), bacteremic pneumonia and meningitis (Bogaert et al., 2004a; Fletcher & 
Fritzell, 2007).  
The introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) had a 
dramatic impact on: i) disease caused by the PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 
and 23F), which was greatly reduced in children, the population targeted by the vaccine, 
and also among the elderly as a consequence of herd immunity (CDC, 2005; Whitney et 
al., 2003), and ii) colonization, where the PCV7 serotypes were replaced by non-PCV7 
serotypes, that nowadays emerge as the dominant nasopharynx colonizers (Dagan et 
al., 1996b; Dagan, 2002; Frazão et al., 2005; Frazão et al., 2010; Sá-Leão et al., 2009). 
As shown by Lloyd-Evans and colleagues (Lloyd-Evans et al., 1996), pneumococcal 
disease originates from nasopharyngeal colonization with the homologous serotype. 
Therefore, the non-PCV7 serotype distribution in the nasopharynx should be used as an 
indicator of potential disease-causing serotypes, as well as antibiotic resistance profiles 
and vaccine coverage. 
In 2001-2003, the first epidemiological study in Portugal on the impact of the PCV7 on 
colonization and antimicrobial resistance shed light on the non-PCV7 serotype flora 
colonizing the nasopharynx of vaccinated children (Frazão et al., 2005). Drug resistant 
pneumococcal strains isolated from the vaccinated group were serotyped and 
genetically characterized by pulsed-field gel electrophoresis (PFGE). After vaccination, 
drug resistant PCV7 serotypes were replaced by drug resistant non-PCV7 serotypes 
presenting different PFGE patterns. The most common drug resistant non-PCV7 
capsular types were 6A, 15A, and 19A (Frazão et al., 2005). 
For the present study, these three serotypes – which together had accounted for 82% of 
the total capsulated drug resistant non-PCV7 strains isolated – were selected for 
characterization in experimental animal models. The goal was to reproduce the capacity 
to colonize and predict the infection potential of the pneumococcal non-PCV7 serotypes 
isolated from the nasopharynx of vaccinated children. Moreover, the effect of capsular 
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type on colonization and blood infection was investigated using otherwise isogenic 
capsular type 3 transformants. 
We provide evidence that nasopharyngeal colonization with the non-PCV7 serotypes 
(6A, 15A, and 19A) results in invasion and infection of adjacent tissues, such as the 
olfactory bulbs, brain, lungs and the middle ear mucosa. All non-PCV7 serotypes 
caused fatal infection when a high bacterial load was reached in the lungs. Serotype 
19A was the only serotype to show propensity to grow in the blood. Expression of the 
type 3 capsule in a 19A genetic background seems to diminish the capacity to colonize, 
while the 6A and 19A genetic backgrounds become highly virulent and cause fatal blood 
infection when expressing the capsular type 3. 
 
4.3. Materials and Methods 
Pneumococcal strains. Our studies used three S. pneumoniae representative strains 
exhibiting capsular types 6A, 15A, and 19A selected from the three major drug resistant 
serotypes found among PCV7 vaccinated children in Portugal (Fig.1 and Table 1). In 
order to select the above mentioned representative strains three selection criteria were 
used: i) belonging to one of the three major drug resistant non-PCV7 serotypes (Fig. 1), 
ii) belonging to the PFGE clonal type with the highest penicillin MIC range, and iii) strain 
with the highest penicillin MIC (Table 1). Capsular transformants exhibiting the type 3 
capsule were generated using 6A and 19A as the parental strains. The transforming 
DNA for the above cited transformations was from the SV35T3 strain, which contains 
the capsular type 3 and a spectinomycin resistance cassette for selection. Bacteria were 
cultured in either C+Y broth (Kharat & Tomasz, 2006), Todd-Hewitt broth, Triptic Soy 
broth (TSB) or Triptic Soy agar (TSA) at 37°C witho ut shaking. For animal studies, 
bacteria were grown in C+Y medium to an OD590 of 0.8, centrifuged, and then 
resuspended in a sterile saline solution (0.9% NaCl) to obtain the desired bacterial 
concentration. In no case were the above mentioned pneumococcal isolates passaged 
in mice before use in any animal experiment. 
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Antimicrobial susceptibility testing. The non-PCV7 strains (6A, 15A, and 19A) were 
tested against a panel of nine antimicrobials by disk diffusion assay (oxacillin, 
chloramphenicol, erythromycin, clindamycin, tetracycline, trimethoprim-
sulfamethoxazole and levofloxacin) and e-test (penicillin and ceftriaxone) as described 
previously (Frazão et al., 2005). Drug resistant non-PCV7 strains are resistant to at least 
one of the antimicrobials tested: penicillin, chloramphenicol, erythromycin, clindamycin, 
tetracycline, trimethoprim-sulfamethoxazole, levofloxacin, and ceftriaxone. 
Pulsed-field gel electrophoresis (PFGE). PFGE was performed after digestion of 
genomic DNA with SmaI using pneumococcal strain R6 and PFGE λ marker (New 
England Biolabs) as molecular weight standards according to an earlier protocol (Sá-
Leão et al., 2000b). PFGE-based clonal types were defined as isolates with ≥80% 
relatedness on the dendrogram analyzed using the Bionumerics software (Applied-
Maths, Sint-Martens-Latem, Belgium). 
Multi-locus sequence typing (MLST). MLST was performed as previously described 
(Sá-Leão et al., 2006). 
Capsule switch methods. Competent cells were prepared by growing bacteria in Todd-
Hewitt broth supplemented with 0.5% yeast extract (THY) until OD590=0.07-0.08. To 
carry out transformation, competent cells were diluted 1:20 in competence medium (TSB 
[pH 8.0], 0.16% bovine serum albumin, 0.01% CaCl2) containing the competent 
stimulating peptide (CSP, ~500 ng) and whole genome transforming DNA (1,000 
ng/mL). CSP1 and CSP2 were used to transform pneumococcal strains 6A and 19A, 
respectively. The transforming DNA was purified from strain SV35T3. The 
transformation reaction (1 mL) was held 4 h at 37°C  in an 1.5 mL eppendorf tube and 
then challenged in TSA plates supplemented with 5% sheep blood and spectinomycin 
(125 µg/mL). Plates were incubated overnight at 37°C with 5% CO2. Transformants 
were confirmed by the typical type 3 mucoid colony morphology, serotyping with specific 
sera (Sorensen, 1993), and PCR amplification of the capsular type 3 operon using 
primers 3F – ATGGTGTGATTTCTCCTAGATTGGAAAGTAG and 3R –
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CTTCTCCAATTGCTTACCAAGTGCAATAACG from Pai and co-workers (Pai et al., 
2006).  
Mice. The protocol for the animal experiments was approved by the Institutional Review 
Board (IRB) of The Rockefeller University (Permit Number: 09073). Groups of 8-week-
old female CD1 outbred mice obtained from the Charles River Laboratories (Charles 
River Laboratories, Wilmington, MA) were used in colonization, lung and blood infection 
models. During the experimental period all mice were monitored on a daily basis for 
survival. Whenever necessary, an intraperitoneal (i.p.) injection of 75 µL of a xylazine 
and ketamine mixture was used to anesthetize the animals (Kharat & Tomasz, 2006). 
CFU numbers inoculated in the mice were confirmed by colony count of serial dilutions 
on TSA supplemented with 5 µg/mL gentamicin. For sampling procedures mice were 
humanely euthanized by CO2 asphyxiation. Mice were given food and water ad libitum.  
Colonization model. Each anesthetized mouse was inoculated intranasally with 10 µL 
of inoculum containing 108 CFU using a 20-µL micropipette. At defined time points after 
the challenge (2, 7, 14, and 21 days) groups of mice were humanely euthanized and 
bacterial numbers were assessed in the nasopharyngeal and middle ear mucosa, 
olfactory bulbs, brain, lungs, and blood. Mouse perfusion was performed before the 
lungs, olfactory bulbs, and brain were harvested in order to avoid possible CFU 
contamination from the blood.  
Lung infection model. Each anesthetized mouse was inoculated intranasally with 50 
µL of inoculum containing 105, 107, or 108 CFU using a 100-µL micropipette. At defined 
time points (2 and 5 h),  after the intranasal challenge with a 108 CFU inoculum, groups 
of mice were humanely euthanized and bacterial numbers were assessed in the lungs, 
and blood.  
Blood infection model. Each mouse was injected intraperitoneally with 500 µL of 
inoculum containing 105 CFU. At defined time points after the intraperitoneal injection 
(0.5, 3, 6, 12, and 24 h) two to three mice were humanely euthanized and bacterial 
numbers were assessed in the blood. 
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Sample collection. To perform the nasopharyngeal wash the trachea was cannulated 
and 500 µL of a saline solution were collected through the mouse’s nose. To sample the 
middle ear mucosa we adapted the procedure used by Lai and colleagues (Lai et al., 
1986). In brief, we injected into the middle ear cavity of each ear 10 µL of sterile saline 
solution by using a 10-µL micropipette which was inserted through the mouse tympanic 
bullae. The saline solution was withdrawn and reintroduced three times (final volume 
recovered, 13 µL/2 ears). Blood collection (300 µL) was done by heart puncture. Using a 
tissue homogenizer (PYREX® Potter-Elvehjem), the lungs, olfactory bulbs and brain 
were homogenized in 1000, 500 or 1000 µL of a sterile saline solution, respectively. 
Resulting solutions from all samples were diluted and plated for CFU counting. 
Definition of infection. Infection was defined as the presence of pneumococci in the 
following tissues: middle ear mucosa, olfactory bulbs, brain, lungs and blood. 
Statistics. Significant differences in CFU numbers were analyzed by using One-way 
ANOVA with Tukey’s multiple comparison test. Survival curves were analyzed using the 
log-rank (Mantel-Cox) test using Prism software from GraphPad Software Inc. In all 
analyses, a maximum error type I of 0.05 was considered for recognition of a significant 
difference. 
 
4.4. Results 
Genetic diversity of the non-PCV7 serotypes. Over a three-year (2001-2003) 
surveillance study in Portugal, a group of 238 children immunized with the PCV7 were 
investigated concerning the vaccine’s impact on colonization and antimicrobial 
resistance (Frazão et al., 2005). Out of 231 drug resistant strains isolated, 66 exhibited 
non-PCV7 capsular types. The most prevalent drug resistant non-PCV7 serotypes were 
6A (6 strains), 15A (26 strains) and 19A (22 strains) that together accounted for 82% of 
the capsulated drug resistant non-PCV7 strains isolated (Fig. 1). 
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Figure 1. Drug resistant non-PCV7 serotypes (n = 66). 
 
 
 
 
 
 
 
 
 
 
Serotype 6A and 15A were relatively homogenous concerning the genetic background, 
presenting only two PFGE patterns each throughout the study period. Serotype 19A was 
more heterogeneous, presenting up to four PFGE lineages along the study (Table 1). 
Nevertheless, among these clonal types we could recognize the dominant clone (the 
one with the higher number of strains), suggesting that a selection pressure of unknown 
source is selecting clones among the non vaccine serotypes. From the clonal types 
found within each one of the more common non-PCV7 serotypes (6A, 15A, and 19A), 
we selected the strains with the highest penicillin MIC for the present study. These 
representative strains were further characterized by MLST, with serotypes 6A, 15A and 
19A exhibiting sequence types ST2191, ST63 and ST276, respectively (Table 1). 
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Major drug resistant
 non-PCV7 serotypes No. of strains PFGE type Antibiotype Sequence Type
1 2 3 6A-II
1 R6
2 6A-I – P(S) clone, MIC range: 0.023 – 0.064 µg/ml (4 strains) P(I) (MIC: 0.19 µg/ml) 2191
3 6A-II – P(I) clone, MIC: 0.19 µg/ml (2 strains) Tet 
6A
1 2 3 15A-I
1 R6 
2 15A-I – P(I) clone, MIC range: 0.125 – 0.19 µg/ml (25 strains) P(I) (MIC: 0.19 µg/ml) 63
3 15A-II – P(S) clone, MIC: 0.016 µg/ml (1 strain) Tet 
15A Da 
E 
1 2 3 4 5 19A-I
1 R6 
2 19A-I – P(I) clone, MIC range: 0.5 – 0.75 µg/ml (12 strains) P(I) (MIC: 0.75 µg/ml) 276
3 19A-II – P(S) clone, MIC range: 0.016 – 0.023 µg/ml (8 strains) SXT 
19A 4 19A-III – P(I) clone, MIC: 0.094 µg/ml (1 strain) Tet 
5 19A-IV – P(I) clone, MIC: 0.19 µg/ml (1 strain) Da 
E 
Non-PCV7 serotypes – Serotypes not included in the PCV7 (7-valent pneumococcal conjugate vaccine). 
P(S) – Penicillin Susceptible (P<0.094 µg/ml); P(I) – Penicillin Intermediate resistant (0.094 µg/ml≤P<1.5 µg/ml) ; E – Erythromycin (E≤15 µg/ml); Da – Clindamycin 
(Da ≤15 µg/ml); Tet – Tetracycline (Te ≤18 µg/ml); SXT - Trimethoprim-sulfamethoxazole (SXT ≤15 µg/ml); 
C – Chloramphenicol (C≤20µg/ml); L – Levofloxacin (L≤13µg/ml),  and TX – Ceftriaxone (TX≤1µg/ml) 
MIC – Minimal Inhibitory Concentration. 
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Colonization potential of non-PCV7 serotypes. A mouse colonization model was 
used to assess the colonization capacity of the representative strains of the non-PCV7 
serotypes. Serotype 6A was maintained in the nasopharynx and olfactory bulbs at all 
time points over the 21-day experimental period. With the exception of day 14, it was 
always present in the brain. In the lungs, serotype 6A was found at days 2 and 21, 
whereas in the middle ear it was found at days 2, 7, and 14, disappearing by day 21. 
Serotype 6A was never found in the blood (Fig. 2). Throughout the experimental period, 
out of 24 mice sacrificed, 79% showed serotype 6A colonization in the nasopharynx, 
while 71% presented serotype 6A in the olfactory bulbs, 42% in the brain, 21% in the 
middle ear, and 17% in the lungs (Table 2). In the nasopharynx, olfactory bulbs, brain 
and lungs serotype 6A was present at average numbers of 101-104 CFU per mouse. By 
contrast, CFU numbers detected in the middle ear were much lower (~1 CFU per 
mouse) (Table 2). All the mice presenting pneumococci in the brain had higher or similar 
CFU numbers in the nasopharynx and olfactory bulbs, with no signs of bacteria in the 
blood. 
Table 2. Colonization and infection with serotype 6A. 
  
Percentage of mice exhibiting colonization and infection 
Time 
(Days) Mice Nasopharynx Olfactory bulbs Brain Lungs Middle ear Blood 
2 5 100% 100% 60% 60% 60% 0% 
7 6 100% 100% 83% 0% 17% 0% 
14 6 67% 50% 0% 0% 17% 0% 
21 7 57% 43% 29% 14% 0% 0% 
Mean 24 79% 71% 42% 17% 21% 0% 
  
Mean CFU per mice exhibiting colonization and infectiona 
Time 
(Days) Mice Nasopharynx Olfactory bulbs Brain Lungs Middle ear Blood 
2 5 7x104 2x103 7x101 6x101 4 0 
7 6 3x104 4x102 5x102 0 <1 0 
14 6 9x102** 1x101 0 0 <1 0 
21 7 1x103** 2x101 7 3 0 0 
Mean 24 2x104 6x102 1x102 2x101 1 0 
aWhen mean CFU is less than 1, <1. The asterisks indicate a significant decrease in the number of CFUs 
compared to day 2 (One-way ANOVA with Dunnett’s multiple comparison test; **p<0,01). 
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Serotype 15A was found in the nasopharynx, olfactory bulbs, lungs, brain, and middle 
ear at all time points over the 21-day experimental period, being only absent from blood 
(Fig. 2). Throughout the experimental period, out of 24 mice sacrificed, 96% presented 
serotype 15A colonizing the nasopharynx, 75% presented it in the olfactory bulbs, 67% 
in the lungs, 54% in the brain, and 46% in the middle ear (Table 3). In the nasopharynx, 
olfactory bulbs, brain and lungs, serotype 15A was present at average numbers of 102-
104 CFU per mouse, whereas CFU numbers were much lower (~1 CFU per mouse) in 
the middle ear (Table 3). Again, all the mice presenting pneumococci in the brain had 
higher or similar CFU numbers in the nasopharynx and olfactory bulbs, with no signs of 
bacteria in the blood.  
Table 3. Colonization and infection with serotype 15A. 
  
Percentage of mice exhibiting colonization and infection 
Time 
(Days) Mice Nasopharynx Olfactory bulbs Brain Lungs Middle ear Blood 
2 6 100% 100% 100% 83% 83% 0% 
7 6 100% 83% 67% 83% 50% 0% 
14 6 100% 67% 33% 83% 17% 0% 
21 6 83% 50% 17% 17% 33% 0% 
Mean 24 96% 75% 54% 67% 46% 0% 
 
 Mean CFU per mice exhibiting colonization and infectiona 
Time 
(Days) Mice Nasopharynx Olfactory bulbs Brain Lungs Middle ear Blood 
2 6 7x104 2x103 5x102 8x103 2 0 
7 6 7x104 5x102 1x102 5x104 <1 0 
14 6 1x104* 7x101 2x101* 8x103 <1 0 
21 6 1x104* 4x101 2x101* 8 <1 0 
Mean 24 4x104 7x102 2x102 2x104 <1 0 
aWhen mean CFU is less than 1, <1. The asterisks indicate a significant decrease in the number of CFUs 
compared to day 2 (One-way ANOVA with Dunnett’s multiple comparison test; *p<0,05). 
Serotype 19A was found in the nasopharynx and the olfactory bulbs at all time points 
over the 21-day period. In the lungs, serotype 19A was always present, but disappeared 
at the last time point (day 21). In the brain and middle ear, this serotype was found only 
at days 2 and 7 after the challenge. 
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Concerning the blood, we only detected the presence of serotype 19A in a single mouse 
at the first experimental time point (day 2) (Fig. 2). Throughout the experimental period, 
out of 24 mice sacrificed, 79% showed serotype 19A colonizing the nasopharynx, 71% 
presented it in the olfactory bulbs, 50% in the middle ear, 38% in the brain and lungs, 
while 4% presented this serotype in the blood (Table 4). In the nasopharynx, olfactory 
bulbs, brain and lungs, serotype 19A was found at average numbers of 102-104 CFU per 
mouse, with the CFU numbers being much lower (6 CFU per mouse) in the middle ear. 
This was the only non-PCV7 serotype found in the blood. Numbers of 7x101 CFU were 
found in a single mouse at day 2 of the experiment (Table 4). All the mice that presented 
pneumococci in the brain displayed higher or similar CFU numbers in the nasopharynx 
and olfactory bulbs, with no signs of bacteria in the blood. The sole exception was a 
single mouse that showed blood infection concomitantly with nasopharyngeal 
colonization and olfactory bulb and brain infection. 
 
Table 4. Colonization and infection with serotype 19A. 
  
Percentage of mice exhibiting colonization and infection 
Time 
(Days) Mice Nasopharynx Olfactory bulbs Brain Lungs Middle ear Blood 
2 6 100% 100% 100% 83% 100% 17% 
7 6 100% 100% 50% 50% 67% 0% 
14 6 83% 67% 0% 17% 33% 0% 
21 6 33% 17% 0% 0% 0% 0% 
Mean 24 79% 71% 38% 38% 50% 4% 
 
 Mean CFU per mice exhibiting colonization and infectiona 
Time 
(Days) Mice Nasopharynx Olfactory bulbs Brain Lungs Middle ear Blood 
2 6 8x104 3x103 1x103 6x104 2x101 3x102 
7 6 5x104 4x102 1x102 5x101 2*** 0 
14 6 4x103* 7 0 2x101 <1*** 0 
21 6 1x103* 3 0 0 0*** 0 
Mean 24 3x104 8x102 3x102 2x104 6 7x101 
aWhen mean CFU is less than 1, <1. The asterisks indicate a significant decrease in the number of CFUs 
compared to day 2 (One-way ANOVA with Dunnett’s multiple comparison test; *p<0,05; ***p<0,001). 
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Figure 2. Colonization model. Mice were intranasally challenged at day 0 with 108 
CFU of the non-PCV7 serotypes 6A (black line), 15A (blue line) or 19A (red line) in 
a 10 µL volume. At days 2, 7, 14, and 21 after inoculation, nasal and middle ear 
washes were performed, and blood, lungs, brain, and olfactory bulbs were 
collected to assess the presence of live pneumococci. Values represent the log10 
of the mean of CFU ± SD of 5 to 7 mice per serotype per time point. The 0 value on 
the y-axis represents the absence of detectable CFU. The asterisks indicate that 
19A differs from 6A and 15A (One-way ANOVA with Tukey's multiple comparison 
test, p<0.001). 
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Lung infection potential of non-PCV7 serotypes. To investigate the potential of the 
non-PCV7 serotypes to cause infection in the lungs, mice were intranasally challenged 
with monocultures of each of the three selected non-PCV7 serotypes and survival was 
assessed over a 7-day period. When using 105 or 107 CFU inocula all mice survived the 
challenge (data not shown), whereas after inoculation with 108 CFU all mice tested (8 
per serotype) died in 24 h (data not shown), showing signs of disease (e.g. piloerection, 
eyelid closure or hunched posture) as soon as 2 h after the intranasal challenge. To 
further evaluate non-PCV7 lung infection, pneumococcal titers were measured in the 
lungs and blood at pre-determined times (2 and 5 h). Lung and blood bacterial titers 
found for each serotype were maintained at the two time points (Table 5). In the lungs, 
the non-PCV7 bacterial titers were maintained fairly constant at high levels (108 CFU 
per mouse). In the blood the lower limit for the bacterial load was 7x104 CFU (6A, 2 h 
after challenge), while the higher was 6x106 CFU (19A, 5 h after challenge). The 19A 
serotype always presented the highest mean bacterial numbers, 4x106 and 6x106 CFU 
at 2 and 5 h, respectively (Table 5). Overall, in this model, the non-PCV7 serotypes 
presented constantly high bacterial titers in the lungs. This may lead to lung tissue 
lesions and a subsequent spill of pneumococci into the blood, where the bacterial 
numbers were always lower than in the lungs (Table 5).  
 
Table 5. Lung infection model. 
  Mean CFU per micea 
  6A  15A 
 
19A 
Time (Hours) Mice Lungs Blood  Lungs Blood 
 
Lungs Blood 
2 2 1x108 7x104  3x108 7x105 
 
1x108 4x106 
5 2 3x108 2x106  2x108 2x105 
 
2x108 6x106 
aWe used two mice per serotype per time point. 
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Blood infection potential of non-PCV7 serotypes. Using an intraperitoneal blood 
infection model we evaluated the potential of non-PCV7 serotypes to cause infection. 
The pneumococcal titers were measured at pre-determined times (0.5, 3, 6, 12, and 24 
h) after infection to assess the pneumococcal blood growth and clearance (Fig. 3). 
Three hours after infection, serotype 19A was not detected and no significant 
differences were found among serotypes 6A and 15A. In all other sampling points no 
significant differences were observed among the three serotypes. However, after the 12 
h time point, serotype 19A showed a tendency to grow, in sharp contrast with the 
remaining two non-PCV7 serotypes, 6A and 15A, which presented propensity to be 
cleared. At 24 h the 19A serotype presented the highest mean number of bacteria in the 
blood (8.8x104 CFU per mouse) when compared to the remaining non-PCV7 serotypes 
(6A and 15A), which displayed mean titers of 6x102 and 5 CFU per mouse, respectively 
(p<0.01) (Fig. 3). Thus, among the non-PCV7 serotypes analyzed, serotype 19A 
appears to be the more “fit” when growing in blood, denoting a higher potential to cause 
blood infection (Fig. 3). 
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Figure 3. Blood infection model. Mice were intraperitoneally challenged at 0 hours 
with 105 CFU of the non-PCV7 serotypes, 6A (Black), 15A (Blue) or 19A (Red). At 
0.5, 3, 6, 12, and 24 hours after injection, blood was collected to assess the 
presence of live pneumococci. Values represent the log10 of the mean of CFU ± SD 
of 2 to 3 mice per serotype per time sampling. The 0 value on the y-axis 
represents the absence of detectable CFU. The asterisks indicate that 19A differs 
from 6A and 15A (One-way ANOVA with Tukey's multiple comparison test, 
p<0.01). 
 
 
 
 
 
 
 
 
Pneumococcal capsule role in colonization and blood infection. The two non-PCV7 
serotype strains, 6A and 19A, were the parental strains transformed to express the 
capsular type 3. The type 3 transformants were named 6A Type 3 or 19A Type 3 if the 
parental strain was 6A or 19A, respectively. Figure 4 shows the morphology of the 
parental and type 3 transformants (mucoid), as well as the PCR amplification results 
confirming the presence of the type 3 operon in the transformants’ genome. 
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Figure 4. Colony morphology of parental and type 3 transformant strains (A), and 
PCR amplification results for the type 3 capsule operon (B). 
 
 
 
 
 
 
 
 
 
 
To test the hypothesis that capsular type affects the colonization potential of non-PCV7 
serotypes, we colonized the nasopharynx of mice with serotypes 6A and 19A and the 
corresponding type 3 transformant strains (6A Type 3 and 19A Type 3). At day 2 after 
the challenge, the CFUs in the nasopharynx of the mice were quantified for comparison 
(Fig. 5). Serotype 6A presented on average 7x104 CFU per mouse, while the 
corresponding type 3 transformant presented 5x104 CFU per mouse. Regarding 
serotype 19A, on average each mouse was colonized with 7x104 CFUs, with the 
corresponding type 3 transformant presenting 9x102 CFU per mouse. Although no 
significant difference was found, it appears that the 19A genetic background is the only 
one negatively affected in the ability to colonize the mouse nasopharynx when 
expressing the type 3 capsule, because it presented a lower CFU number (Fig. 5). 
A) Colony morphology 
Parental 
B) PCR amplification of the type 3 capsule operon 
6A 6A Type 3 
19A 19A Type 3 
Transformant 
1    2    3    4    5   6 
Legend: 
1 – 1kb ladder 
2 – 6A Type 3 
3 – 19A Type 3 
4 – Positive control (SV35T3) 
5 – Negative control (No DNA) 
6 – 1kb ladder 
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Figure 5. Capsule role in colonization. Mice were intranasally challenged at day 0 
with 108 CFU of 6A (full circles), 6A Type 3 transformant (open circles), 19A (full 
triangles) or 19A Type 3 transformant (open triangles) in a 10 µL volume. At day 2 
after inoculation, nasal washes were performed to assess for the presence of live 
pneumococci. CFUs for each mouse are plotted. Horizontal bars indicate the 
mean CFU titer. The 0 value on the y-axis represents the absence of detectable 
CFU. 
 
 
 
 
 
 
 
 
 
To investigate whether the capsular type affects the blood infection potential of the non-
PCV7 serotypes, we infected groups of mice via the intraperitoneal route with serotypes 
6A or 19A and the corresponding type 3 transformant strains (6A Type 3 and 19A Type 
3). Following infection, mice survival was assessed over a 7-day period (Fig. 6). When 
the infection inoculum of serotypes 6A or 19A was 103 or 105 CFU per mouse, the vast 
majority of the animals survived the challenge without showing any signs of disease 
(Fig. 6). However, if the mice were challenged with only 103 CFU per mouse using the 
type 3 transformant strains, all animals died before day 7, presenting signs of disease as 
soon as one day after the intraperitoneal challenge (Fig. 6). 
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Figure 6. Capsule role in blood infection. Isogenic strains expressing either 
capsular types 6A or 19A and the corresponding capsular type 3 transformants 
were injected into the peritoneal space of CD1 mice. Survival was followed to 
assess the virulence potential of the capsular types. Five mice per 
serotype/inoculum were tested. Survival curves for parental strains (6A and 19A) 
were significantly different from the corresponding type 3 transformants (Mantel-
Cox test, p<0.01). 
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4.5. Discussion 
As pneumococcal disease is initiated with the establishment of the carrier state, 
serotype distribution in the nasopharynx should constitute a good indicator of future 
pneumococcal disease agents. The impact of PCV7 in colonization was firstly 
investigated in Portugal in 2001-2003, with the major non-PCV7 serotypes being 
isolated and characterized regarding capsular type, genetic background and 
susceptibility to antimicrobials. Data showed that within the major drug resistant non 
vaccine serotypes a dominant clone could be identified suggesting that capsular type 
selection induced by PCV7 is accompanied by a clonal type selection (Table 1). 
Within the major drug resistant non-PCV7 serotypes – 6A, 15A, and 19A – we identified 
the clonal types presenting the higher penicillin MIC range, from where we selected 
representative strains presenting the highest penicillin MIC. These representative 
strains, exhibiting serotypes, 6A, 15A, and 19A, were characterized using experimental 
animal models of colonization and disease. By testing these non-PCV7 serotypes in 
animal models, we aimed at mimicking their known capacity to colonize the human 
nasopharynx (Frazão et al., 2005) and predicting their virulence potential. 
Using a mouse model of colonization we were able to reproduce the known high 
colonization capacity of the non-PCV7 serotypes, as the three selected serotypes 
colonized the mice nasopharynx with a mean bacterial number of 104 CFU per mouse 
over a 21-day study period. The steady colonization of the nasopharynx with multi-drug 
resistant non-PCV7 serotypes during such a long experimental period may constitute a 
suitable system to test the efficacy of new antimicrobials or vaccines that target 
colonization (mucosal vaccines). 
As a result of the establishment of colonization all three non-PCV7 serotypes behaved 
similarly and were capable of invading and infecting nasopharynx adjacent tissues such 
as the olfactory bulbs, brain, lungs and the middle ear mucosa. Indicating propensity to 
cause infection, serotype 19A presented significantly higher bacterial titers than the 6A 
and 15A serotypes in the middle ear mucosa (p<0.001). Additionally, it was the only 
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non-PCV7 serotype found in the blood of a mouse two days after nasopharynx 
colonization. Virulence potential was also exhibited by serotype 15A which grew easily 
in the lungs, presenting high bacterial numbers along the experimental period. 
In accordance with previous data (Marra & Brigham, 2001; van Ginkel et al., 2003), 
virtually all colonized mice with brain infection did not present bacteria in the blood, 
clearly showing that pneumococci can enter the brain directly from the nasopharynx in 
the absence of blood infection. The possibility that this direct route occurs in humans 
highlights the extreme importance of inhibiting nasopharyngeal colonization to prevent 
seeding of the brain with bacteria. Vaccines that do not target colonization would fail to 
prevent infection through this route as previously suggested (van Ginkel et al., 2003).  
To gain further insight into the potential to cause infections we tested the three non-
PCV7 serotypes in lung and blood infection models. All serotypes tested in the lung 
infection model were lethal when using high inocula (108 CFU per mouse), killing all the 
mice as early as 24 h after the challenge. Moreover, the titer of bacteria in the lungs was 
always higher (~108 CFU per mouse) than in the blood. Such a high pneumococcal titer 
could enable lung tissue lesions leading to constant blood poisoning. With lower inocula 
(107 or 105 CFU per mouse), no mice were killed by any of the non-PCV7 serotypes, 
suggesting that death of the mice through lung infection is mainly dependent on the 
bacterial load reached in this organ. Using the blood infection model we found that 
serotypes 6A (clone ST2191) and 15A (clone ST63) were not fit to grow in blood, 
contrarily to what was observed for serotype 19A (clone ST276). This 19A clone was 
more fit than serotypes 6A and 15A clones when growing in blood, presenting higher 
bacterial numbers in the blood 24 h after challenge (p<0.01), while the latter serotypes 
started to be cleared from the blood after 12 h. These data suggest that serotype 19A 
(clone ST276), initially isolated in 2001 from the nasopharynx of healthy children 
vaccinated with PCV7 (Frazão et al., 2005), has the capacity to cause blood infection. In 
fact, three recent studies released in 2009 and 2010 (Aguiar et al., 2009; Ardanuy et al., 
2009b; Mahjoub-Messai et al., 2009), have reported that this very same serotype 19A, 
presenting the same genetic background, ST276, is a major cause of invasive disease 
both in children and adults in Portugal, Spain and France. Moreover, in 2009, this 19A 
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clone was reported to be a major cause of otitis media in Israel, being associated with 
high levels of antibiotic consumption (Dagan et al., 2009). This association of the 19A 
ST276 clone with high antibiotic consumption is a scenario that is mirrored in Portugal, 
specifically in children attending day-care center facilities from whom we isolated our 
multi-drug resistant 19A-ST276 strain in 2001 (Frazão et al., 2005).   
The variability in the capacity to cause site-specific disease has been reported not only 
among serotypes, but also across pneumococcal genetic backgrounds (Forbes et al., 
2008; Obert et al., 2006; Pettigrew & Fennie, 2005; Pettigrew et al., 2006; Sandgren et 
al., 2004; Shouval et al., 2006; Sjostrom et al., 2006). Therefore, understanding the 
basis of pneumococcal virulence requires disentangling the impact of capsular and non-
capsular genetic contributions. Here, we created otherwise isogenic capsular Type 3 
transformants using 6A and 19A as the parental strains to overcome the variability issue 
and infer about the capsule role in colonization and blood infection. The 6A Type 3 
transformant showed the same ability to colonize as the 6A parental strain, whereas the 
19A Type 3 transformant showed diminished capacity to colonize when compared to its 
parental strain. We therefore conclude that colonization ability depends not only on the 
capsular type, but also on the genetic background that expresses it. Regarding blood 
infection, all mice intraperitoneally challenged with any of the type 3 transformants died 
in less than seven days, in sharp contrast to what was observed with the parental 
strains. Both the 6A and 19A parental genetic backgrounds allowed full expression of 
the typical virulence associated to the type 3 capsule causing fatal blood infection. Thus, 
it appears that the virulence potential, at least in this particular case, is more dependent 
on the capsular type exhibited than on the genetic background of the pneumococcal 
strain. 
The present work reinforces the importance of coupling epidemiological and animal 
studies in order to predict pneumococcal virulence of the major serotypes selected after 
vaccine pressure. Evaluation of the virulence potential of other major serotypes 
colonizing the nasopharynx is required to anticipate the impact of the next generation of 
capsular vaccines. Additionally, further research will be crucial in the identification of 
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non-capsular virulence factors, which may aid in the development of universal strategies 
for prevention and control of pneumococcal disease. 
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5. Concluding remarks and future perspectives  
The 7-valent pneumococcal conjugate vaccine produced a massive shift in the human 
pneumococcal nasopharyngeal flora. The high efficacy of the conjugate vaccine 
completely transformed the pneumococcal population structure, wiping out the vaccine 
serotypes and leading to the emergence of “new” serotypes, the so-called non vaccine 
types (non-PCV7 serotypes). The dramatic impact of the conjugate vaccine motivated 
numerous studies in a multitude of fields including immunology, epidemiology, drug 
resistance, and genetics. 
This thesis aims to sum up the massive effect of this vaccine on pneumococcal 
colonization in Portugal, examining at the same time the virulence potential of the new 
pneumococcal players, the non-PCV7 serotypes. To achieve these objectives, a 
common set of techniques was used: serotyping, antimicrobial testing, pulsed-field gel 
electrophoresis (PFGE), multilocus sequence type (MLST), and mouse models of 
colonization and disease. 
Before the study published in The Pediatric Infectious Disease Journal in 2005 and 
presented in Chapter II of this thesis, the effect of PCV7 on colonization was unknown in 
Portugal. This was the first work to evaluate the impact of PCV7 on colonization, with 
particular emphasis on drug resistance and genetic background of the non vaccine 
types (NVTs) carried by Portuguese children attending day-care centers (DCCs).  
Similarly to what has been reported in several studies (Huang et al., 2005; Huang et al., 
2009; Lakshman et al., 2003; Pelton et al., 2004), vaccination with PCV7 did not affect 
the global carriage of pneumococcal strains (susceptible and resistant). Due to the fact 
that in the pre-PCV7 era most drug resistant pneumococci expressed a limited number 
of serotypes included in the vaccine, it was expected that PCV7 could reduce drug 
resistance carriage rates (Joloba et al., 2001; Wuorimaa & Kayhty, 2002). We therefore 
decided to study in more detail the impact of the PCV7 on drug resistant strains. In 
agreement with previous studies (Dagan et al., 1996a; Dagan et al., 1997; Dagan, 2002; 
Dagan et al., 2002; Dagan et al., 2003), the vaccine was found to reduce colonization 
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with vaccine type (VT) drug resistant strains. However, in contrast with earlier reports 
(Dagan et al., 1996a; Dagan et al., 1997; Dagan, 2002; Dagan et al., 2002; Dagan et al., 
2003; Klugman, 2001; Piffer, 2002), total carriage rate of drug resistant strains did not 
decline after vaccination in Portugal. Concomitantly with the decrease of drug resistant 
VT strains there was also an increase of drug resistant NVTs. 
The pressure exerted by the PCV7 vaccine led to a phenomenon termed serotype 
replacement colonization. Furthermore, drug resistant NVTs presented genetic 
backgrounds different from the ones of the VTs. The replacement of drug resistant VTs 
by NVTs, also drug resistant and presenting unusual genetic backgrounds, is very likely 
the result of a combined effect of vaccine pressure and undiminished use of antibacterial 
agents. 
The emergence of drug resistant NVTs is still a matter of debate. Why are these NVTs 
also drug resistant? One may hypothesize that drug susceptible NVTs acquire drug 
resistant determinants from the receding drug resistant VTs, or that drug resistant NVTs 
that preexisted as minor components in the nasopharynx emerge when the more fit VTs 
disappear under the vaccine pressure. The latter alternative appears likely given that 
some drug resistant non vaccine serotypes were identified at the onset of the study. 
As colonization is the initial step to pneumococcal disease, one may wonder if these 
NVTs can cause disease. Indeed, since the first studies after the PCV7 introduction, 
several pieces of evidence support the fact that serotype replacement occurs not only 
during colonization, but also in disease. In fact, the non vaccine serotypes and 
associated clonal types found in the present study (6A, 10A, 15A/C, 19A, 23A and 33F) 
have been associated with pneumococcal disease in the years following PCV7 
introduction (Brueggemann et al., 2003; Doit et al., 2002; Eskola et al., 2001; 
McEllistrem et al., 2003; Porat et al., 2004; Serrano et al., 2004) and nowadays 
(Ardanuy et al., 2009a; Ardanuy et al., 2009b; Dagan et al., 2009; Mahjoub-Messai et 
al., 2009). 
The studies described in Chapter II represent the first observations concerning the effect 
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of PCV7 on pneumococcal carriage in Portuguese children. The study provided unique 
and vital information on the most common drug resistant non vaccine serotypes and 
associated clonal types that emerged substituting the PCV7 serotypes. Worth of note is 
the fact that resistance maintenance in our setting seems to imply that reduction of the 
pneumococcal drug resistance rates requires a combination of pneumococcal vaccines 
and a reduction in the use of antimicrobial agents. 
In Chapter III, the impact of PCV7 on colonization was evaluated by analyzing the effect 
of one dose of the vaccine, not only among single, but also among multiple carriers. The 
rationale underlying such a study was the fact that: i) in disease a single dose seems to 
be sufficient to prevent infections caused by VTs (Barzilay et al., 2006; Whitney et al., 
2006), and ii) studying multiple colonization can provide a more complete view of the 
pneumococcal population structure to evaluate the real extent of the PCV7 effect.  
The study design where the same child was sampled one month apart was quite 
advantageous as it allowed evaluation of the effect of the PCV7 not only at the 
population, but also at the individual level. Moreover, for the first time in Portugal, the 
effect of PCV7 on colonization was investigated not by analyzing a single colony by 
carrier, but by studying multiple colonization. 
Our expectations were confirmed and similarly to what happens with more than one 
dose (Dagan et al., 1996a; Dagan, 2002; Frazão et al., 2005; Kilpi et al., 2001; Mbelle et 
al., 1999; O'Brien et al., 2007), a single dose of PCV7 indeed decreased VT 
colonization. A replacement phenomenon was also found in the present study, with 
NVTs substituting serotypes included in the vaccine both at the population and the 
individual level. 
Owing to the study design it was possible to evaluate the PCV7 impact on colonization, 
not only by prevalence comparison between vaccinated and control groups, but also by 
identifying the actual mechanism of the vaccine’s effect. By observing the colonization 
patterns among vaccinated children, ecological mechanisms such as clearance, de novo 
acquisition, unmasking, and maintenance, were examined. In accordance with previous 
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studies (Bogaert et al., 2004b; Dagan et al., 2003; Klugman, 2001; Whitney et al., 2006), 
the results obtained suggest that conjugate vaccines reduce VT carriage by preventing 
de novo acquisition rather than clearance. An additional mechanism of the vaccine’s 
effect appears to be the enhancement of NVT unmasking in vaccinated children. 
Assessment of the latter mechanism was only possible due to the study of multiple 
colonization. 
The studies described in Chapter III provide novel and valuable information on PCV7 
single vaccine dose schedule. The findings were that, as early as one month after 
vaccination with a single dose, PCV7 causes serotype replacement of VT by NVT 
isolates at the population and individual levels, with the mechanisms of the vaccine’s 
effect being the prevention of VT de novo acquisition and enhancement of NVT 
unmasking. 
The study presented in Chapter IV is a complement to the epidemiological studies 
described above. As the first step to pneumococcal disease is the establishment of the 
carrier state, the pneumococcal population in the nasopharynx should constitute a good 
indicator of future pneumococcal disease agents. Therefore, representative strains of 
the most common non-PCV7 serotype/clonal types isolated from the nasopharynx of 
children included in the study presented in Chapter II were selected to investigate their 
virulence potential using animal models. 
The three representative strains expressed capsular types, 6A, 15A and 19A. Using a 
mouse model of colonization the first finding in this study was the fact that shortly after 
colonization of the nasopharynx each of these three serotypes were capable of 
disseminating to adjacent tissues such as the olfactory bulbs, brain, lungs and the 
middle ear mucosa. Serotype 19A demonstrated a higher potential to cause blood 
infection, while serotype 15A was prone to cause lung infection. Worth of note was the 
fact that all these serotypes were able to invade the brain without causing blood 
infection. This finding is in agreement with previous studies that reported this very same 
phenomenon (Marra & Brigham, 2001; van Ginkel et al., 2003), explaining it by 
retrograde axonal transport along olfactory neurons into the brain. The possibility that 
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this phenomenon can occur in humans highlights the importance of inhibiting 
nasopharyngeal colonization to prevent seeding of the brain.  
When the virulence potential of the selected serotypes was assessed in a lung infection 
model, all three caused lethal infections at high bacterial loads and no killing at lower 
doses, indicating that lethal infection of the lungs was dose-dependent.  
By using an intraperitoneal model of blood infection we found that  serotype 19A was the 
most fit growing in blood, suggesting that serotype 19A (clone ST276), initially isolated 
in 2001 from the nasopharynx of healthy children vaccinated with PCV7 (Frazão et al., 
2005), has the capacity to cause blood infection. In fact, serotype 19A associated to 
ST276  is currently a major cause of invasive disease both in children and adults in 
Portugal, Spain and France (Aguiar et al., 2009; Ardanuy et al., 2009b; Mahjoub-Messai 
et al., 2009). In 2009, this very same 19A clone was reported to cause otitis media in 
Israel, being associated with high levels of antibiotic consumption (Dagan et al., 2009). 
Interestingly, high antibiotic consumption is a scenario mirrored in Portugal, specifically 
in children attending DCC facilities from whom we isolated our 19A (ST276) strain, 
which is multidrug resistant (Frazão et al., 2005).   
To assess the role of the capsule versus the genetic background in colonization and 
disease, otherwise isogenic strains of serotypes 6A and 19A expressing type 3 capsule 
were generated. In our setting we found that the colonization ability depended not only 
on the capsular type, but also on the genetic background that expresses it. Concerning 
blood infection potential, virulence appears to be more dependent on the capsular type 
expressed than on the genetic background. 
In Chapter IV natural colonization isolates selected by the PCV7 vaccine were tested in 
mouse models, enabling conclusions on the virulence traits of these emergent serotypes 
selected by the vaccine pressure. This reinforces the importance of coupling 
epidemiological and animal studies in order to predict the virulence potential of 
serotypes selected by present and future pneumococcal vaccines.    
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In summary, the studies presented in this thesis i) documented – for the first time – the 
massive shift in colonization operated by the pneumococcal conjugate vaccine in 
Portugal; ii) provided insights into the mechanisms of serotype change using a model 
study with short exposure to the vaccine and iii) allowed testing virulence traits of the 
emergent non vaccine type pneumococci using animal models. 
The foremost conclusion of the effect of PCV7, not only at the colonization but also at 
the disease level, is that there is a serotype replacement phenomenon. If, on one hand, 
we attribute the vaccine serotype decline to the effect of PCV7, the subsequent 
emergence of only certain specific non vaccine serotypes/genotypes is not yet fully 
explained. What are the characteristics that make certain non vaccine serotypes and 
specific genotypes within them so successful after vaccination? 
For years, pneumococcal studies have been centered on the study of single isolates. 
However, in nature, inter and intraspecies interactions exist. Bearing this in mind, one 
can wonder what the role of these interactions on colonization and disease is. Finally, 
future efforts must not focus exclusively on the microorganism side as the development 
of systems designed to better understand the interaction between host and microbe is of 
utmost importance. 
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